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1. INTRODUCTION 
In intensive care units (ICU), care is provided to critically ill patients requiring 
intensive and specialised medical and nursing treatment, enhanced monitoring 
and multiple modalities of physiologic organ support to sustain life during a 
period of life-threatening organ system insufficiency (Marshall et al., 2017).  
Naturally, multiple organ dysfunction is a frequent cause of morbidity and 
mortality in intensive care patients. In health, the integration of different organ 
systems maintains homeostasis, while an acute or chronic dysfunction of any 
organ may cause dysregulation in another through a series of complex inter-
actions (Armutcu, 2019). Several examples of such organ cross-talk are well 
described and acknowledged, e.g., the cardiorenal and hepatorenal syndromes, 
hepatic encephalopathy and others. Similarly, the theory of gut as a motor for 
multiple organ failure originates from already 35 years ago, initially focusing on 
hyperpermeability and bacterial translocation into the circulation (Carrico, 
1986). More recently, other pathways of gut-derived distant organ damage have 
been brought to light, including the gut lymph hypothesis, increased enterocyte 
apoptosis and alterations in the microbiome (Klingensmith & Coopersmith, 
2016). Despite recent rapid advances in the diagnosis, treatment and replace-
ment therapies of other organs, the clinical assessment of gastrointestinal (GI) 
function in critically ill patients continues to rely on the time-tested, but un-
structured and operator-dependent clinical examination. The GI tract is not 
incorporated in any of the currently used disease severity and multiple organ 
dysfunction assessment scores, hindering research in the field. Accordingly, 
treatment options targeting the gut in critically ill patients, outside enteral nutri-
tion (EN), are scarce.  
The present dissertation concludes studies performed in the fields of enteral 
nutrition, intra-abdominal hypertension (IAH) and gastrointestinal dysfunction 
in critically ill patients. Research in this dissertation is a continuation of the 
work done in the field of gastrointestinal problems in intensive care, carried out 
over the last decades in the Department of Anaesthesiology and Intensive Care 
of the University of Tartu and the Tartu University Hospital.  
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2. REVIEW OF THE LITERATURE 
To gain insight into the management of gastrointestinal problems in intensive 
care, relevant aspects of nutrition, abdominal and gastrointestinal signs and 
symptoms as well as biomarkers need to be reviewed. 
 
 
2.1. Nutrition in critical illness 
Normal oral nutrition is seldom possible in critically ill patients (Bendavid et 
al., 2017). Inability to eat is often caused by disorders of consciousness or swal-
lowing or treatments such as sedation and mechanical ventilation. An important 
consideration in this regard is also the sickness-associated anorexia, a concept 
recognised in humans and other animals already for centuries (van Niekerk et 
al., 2016a). Indeed, loss of appetite seems prevalent in intensive care patients 
with only around 30% reporting hunger or a desire to eat (Bendavid et al., 
2017).  
On the other hand, the critical state brought on by, for example, a severe 
infection, trauma or single or multiple organ failure is often accompanied by in-
tense catabolism and increased energy expenditure. With no significant protein 
reserves in the human body, proteins mainly from the skeletal muscle are 
degraded into amino acids, and used to satisfy the needs for regeneration of 
tissues and synthesis of acute phase proteins. Over the last decades, develop-
ments in intensive care medicine have made it possible to sustain life longer 
than ever before, ultimately reducing mortality, but at the same time, for some 
patients prolonging the critical illness and catabolic state. Indeed, the develop-
ment of large cumulative caloric and protein deficits during the stay in ICU has 
been observed to associate with infections, longer length of stay, and mortality 
(Villet et al., 2005; Dvir et al., 2006; Alberda et al., 2009; Weijs et al., 2019). 
Therefore, the question arises whether artificial nutrition can counteract the 
catabolic state and diminish wasting of the body reserves.  
Closely tied to sickness-associated anorexia and likely promoted by it is 
autophagy, a cellular reparation and recycling process in which damaged orga-
nelles, proteins and macromolecules are degraded, ensuring endogenous energy 
production and substrates for biosynthesis (van Niekerk et al., 2016b). Auto-
phagy plays a key role in energy homeostasis, immune regulation and a generic 
response to various stressors (van Niekerk et al., 2016a), thereby also mediating 
organ function recovery in critical illness (Van Dyck et al., 2018). Discovery 
and acknowledgement of the process of autophagy has had significant impli-
cations on the nutrition of critically ill patients. Autophagy is thought to be 
especially important in the early phase of acute severe illness to assure clea-
rance of cellular damage, and is suppressed by nutrition. This is thought to be 
one explanation for the results of the EPaNIC study showing early full nutrition 
being associated with clinically significant complications, including muscle 
weakness, more frequent infections and longer length of stay in ICU (Casaer et 
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al., 2011; Van Dyck et al., 2018). Furthermore, the endogenous energy produc-
tion sustained by stress hormones cannot be abolished with exogenous nutrients 
(Preiser et al., 2014), possibly resulting in overfeeding if early high volume 
nutrition is attempted. These findings together have led to the hypothesis that 
restrictive energy provision or trophic feeding is beneficial in the early stages of 
critical illness, confirmed by several randomised controlled trials comparing 
restrictive caloric intake to full energy provision in this setting (Arabi et al., 
2011; Braunschweig et al., 2015; van Puffelen et al., 2018). Even if no signi-
ficant differences in terms of mortality could be demonstrated (Rice et al., 2011, 
2012; Arabi et al., 2015), the studies show that early trophic feeding is better 
tolerated (Rice et al., 2011, 2012). Full enteral nutrition in critically ill patients 
with shock may be associated with more frequent GI symptoms and life-
threatening bowel ischaemia (Reignier et al., 2018). 
Most intensive care patients require artificial nutrition, i.e. enteral or paren-
teral nutrition or a combination thereof (Bendavid et al., 2017). EN refers to the 
administration of food into the stomach (prepyloric) or more distal parts of the 
GI tract (postpyloric), while with parenteral nutrition (PN) nutrients are de-
livered intravenously. EN is considered the optimal method when eating is not 
possible, being more physiological and cheaper. EN is acknowledged to atte-
nuate stress and modulate the immune response (Windsor et al., 1998; Bear et 
al., 2017). PN has historically been associated with more frequent bacterial and 
fungal infections compared to EN, resulting in significant morbidity and mor-
tality (Koretz et al., 2001), but these findings were not confirmed in the most 
recent large trial (Harvey et al., 2014). Currently, early enteral nutrition (EEN), 
defined as EN started within 48 hours of admission to ICU, is advocated in the 
societal guidelines, with a low starting dose and later use of supplemental 
parenteral nutrition if protein and caloric needs are not met by EN alone 
(McClave et al., 2016; Reintam Blaser et al., 2017; Singer et al., 2019). A 
benefit of EEN over delaying EN seems to be a lower incidence of infectious 
complications (Reintam Blaser et al., 2017).  
Although research in the last decade has cautioned against early high volume 
feeding of critically ill patients and slow initiation of feeding is a standard of 
care in most patients, underfeeding continues to be a major problem, especially 
among those at high risk of complications as demonstrated by Heyland and co-
authors. In this observational study including 3390 mechanically ventilated pa-
tients from 26 countries, the prevalence of underfeeding, defined as failure to 
achieve 80% of energy targets during up to 12 days of ICU stay, was 65% 
among long-staying patients (ICU stay >7 days) and nearly 80% in patients with 
a modified Nutrition Risk in Critically Ill score of ≥5 (Heyland et al., 2015).  
Practically, EN is administered as a continuous infusion, starting with low 
rates of 10–20 ml/h with careful attention to abdominal and gastrointestinal 
symptoms. The desired infusion rate should be achieved between days 3 and 7, 
with 70%–100% of resting energy expenditure considered adequate (Singer et 
al., 2019). The suggested standard in determining the energy expenditure of a 
critically ill patient is indirect calorimetry (Singer et al., 2019). In real practice, 
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the caloric prescription is predominantly based on values calculated with pre-
dictive equations or weight-based formulae (Heyland et al., 2015). Such 
approach is particularly inaccurate, achieving a result of ±10%  of energy 
expenditure measured by IC in only a third of patients (Zusman et al., 2019), 
Thus,  over- and underfeeding becomes frequent if IC is not used.   
The use of feeding protocols is encouraged by several societies to achieve 
early initiation, slow and gradual increase of EN together with a protocolised 
management of possible GI problems (McClave et al., 2016; Reintam Blaser et 
al., 2017; Singer et al., 2019). Usual features of feeding protocols include a time 
and indication to start feeding, a target feeding rate, details on feed advance-
ment strategies, instructions on how to handle gastric residual volumes (GRV) 
and details on when to decrease or stop nutrition or consider an alternative 
feeding route. An increase of nutrients administered is a common observation in 
studies evaluating the effects of feeding protocols (Arabi et al., 2004; Compton 
et al., 2014; Doig et al., 2008; Mackenzie et al., 2005), with also a positive 
effect on treatment outcome in some studies (Martin et al., 2004; Taylor et al., 
1999; Heyland et al., 2013).  
Contraindications to oral and enteral nutrition include several severe general 
and gastrointestinal conditions where feeding may be harmful. The list includes 
uncontrolled shock, uncontrolled hypoxemia and acidosis, large gastric aspirate 
(>500 mL in 6 hours), continuing upper GI bleeding, bowel ischaemia or 
obstruction, abdominal compartment syndrome (ACS) and a high-output fistula 
in the absence of a distal feeding access (Reintam Blaser et al., 2017; Singer et 
al., 2019).  
Feeding intolerance (FI) is a clinical scenario where enteral feeding is not 
tolerated. FI is considered present if EN has to be stopped due to any clinical 
reason or at least 20 kcal per kilogram of body weight per day cannot be 
achieved within 3 days after the start of the feeding attempt (Reintam Blaser et 
al., 2012). Considerable variation exists in  definitions of FI used in clinical 
studies (Reintam Blaser et al., 2014b). Most often it is diagnosed on the basis of 
large GRV alone, with a median value of 250 mL used across studies (Reintam 
Blaser et al., 2014b). Prevalence of FI depends significantly on the definition 
but is in the range of 24–45% of all ICU patients (Reintam Blaser et al., 2014b; 
Hu et al., 2017; Heyland et al., 2021). Several studies with GI symptom-based 
definitions of FI have demonstrated an association between FI and poor 
treatment outcome (Mentec et al., 2001; Lam et al., 2007; Nguyen et al., 2007; 
Reintam et al., 2008a; Shimizu et al., 2011; Gungabissoon et al., 2015; Heyland 
et al., 2021), highlighting the importance of GI symptoms in assessment of GI 
function.  
Taken together, nutrition of a critically ill patient is a complex topic, with 
many questions still insufficiently answered. EEN with gradual progression 
towards the goal is the suggested standard. However, there is no consensus 
regarding the optimal calorie target in the acute phase of critical illness and 
methods to reach it.  
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In study I nutritional practices, complications and outcomes were compared 
before and after implementing an enteral feeding protocol in mechanically 
ventilated ICU patients at the 1st ICU of the Tartu University Hospital. 
 
 
2.2 Gastrointestinal signs and symptoms 
Gastrointestinal signs and symptoms are frequent, with at least one symptom 
occurring in around 60% of patients (Reintam et al., 2009; Reintam Blaser et 
al., 2013). Reported prevalences of single symptoms vary considerably, partly 
owing to different definitions, for example 20–83% for constipation and 3.3–
78% for diarrhoea (Hay et al., 2019).The symptoms can be related to the ab-
dominal pathology that necessitated admission to ICU, or may indicate GI dys-
function/failure developing as a part of multiple organ dysfunction during inten-
sive care.  The occurrence GI symptoms on admission day or their development  
later during ICU stay are both associated with impaired outcome in several 
observational studies (Reintam et al., 2009; Reintam Blaser et al., 2013).  
GI symptoms have been historically a cornerstone in recognizing and diag-
nosing of GI dysfunction in critically ill patients. However, these symptoms are 
often nonspecific, and their assessment subjective and poorly reproducible. 
Additional difficulty in this field has been the absence of uniform definitions. In 
2012, the Working Group on Abdominal Problems of the European Society of 
Intensive Care Medicine (ESICM) aimed to overcome the latter issue by 
standardizing the definitions of common GI symptoms (Reintam Blaser et al., 
2012). List of these symptoms with definitions and brief overview of their 
significance is given below.  
 
Vomiting is the occurrence of any visible regurgitation of gastric content irrespec-
tive of the amount (Reintam Blaser et al., 2012). In intensive care patients, 
vomiting (an active forceful event) is often indistinguishable from regurgitation (a 
passive effortless event), therefore these two should be assessed together 
(Reintam Blaser et al., 2012). A frequent adverse event among postoperative 
patients admitted to intensive care units is postoperative nausea and vomiting, 
occurring in 30% of the overall surgical population and as much as 80% of 
patients with risk factors (Gan et al., 2020). Other well-known causes for 
vomiting in critically ill patients are various abdominal and central nervous 
system pathologies and use of certain medications, e.g. chemotherapy or opioids 
(Gan et al., 2020; Reintam Blaser et al., 2015b). The incidence of vomiting in 
critically ill patients is 15–38% (Reintam et al., 2009; Reintam Blaser et al., 2013; 
Virani et al., 2019). Nausea and vomiting are associated with patient discomfort, 
but also serious complications such as dehydration, malnutrition, electrolyte and 
acid base disorders and surgical site disruption (Thompson, 1999; Gennari & 
Weise, 2008). An immediately life-threatening complication is tracheal aspiration 
of gastric contents, potentially leading to aspiration pneumonitis or pneumonia, 
acute respiratory failure and death (Raghavendran et al., 2011).  
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Diarrhoea is defined as having three or more loose or liquid stools per day with 
a stool weight greater than 200–250 g/day (or greater than 250 ml/day) (Rein-
tam Blaser et al., 2012). Several studies estimate the prevalence of diarrhoea in 
critically ill patients to be 13–22% (Reintam et al., 2009; Reintam Blaser et al., 
2013; Thibault et al., 2013; Tirlapur et al., 2016), however a recent systematic 
review shows a range of 3‒78%, demonstrating significant differences in patient 
selection and diagnostic criteria in available studies (Hay et al., 2019). Common 
causes for diarrhoea in the critically ill include infectious (mainly bacterial, 
notably Clostridioides difficile) and non-infectious conditions. Among the 
latter, enteral nutrition and drugs (prokinetic, antibiotics, laxatives) are the most 
frequent, whereas bowel ischaemia and hypoalbuminemia are also important 
causes of diarrhoea (Wiesen et al., 2006; Thibault et al., 2013; Tirlapur et al., 
2016). Among 1207 ICU patients experiencing diarrhoea, an infectious cause 
was identified in only 9.2%, while the use of laxatives or enemas/suppositories 
preceded the development of diarrhoea in 20.2% and 13.1%, respectively 
(Tirlapur et al., 2016). Diarrhoea may develop as a result of EN, influenced by 
the composition of the feed as well as the site and method of EN (Wiesen et al., 
2006). EN covering >60% of energy target has been identified as a risk factor 
for diarrhoea (Thibault et al., 2013). Diarrhoea is known to be associated to 
decreased delivery of nutrients via the enteral route and if left uncorrected, with 
fluid loss as well as acid-base and electrolyte disorders (Wiesen et al., 2006). 
Diarrhoea is independently associated with longer length of stay and a greater 
mortality in ICU (Tirlapur et al., 2016). 
 
Gastrointestinal bleeding in the critically ill is defined as any bleeding into the 
GI tract lumen, confirmed by macroscopic presence of blood in vomited fluids, 
gastric aspirate or stool (Reintam Blaser et al., 2012). The prevalence is depen-
dent on the extent or nature of bleeding. An earlier study revealed that most 
critically ill patients experience endoscopically detectable mucosal erosions and 
subepithelial haemorrhage within 24 hours of admission to ICU (Mutlu et al., 
2001). In the current era of frequent proton pump inhibitor use, clinically 
important GI bleeding (defined as overt bleeding and at least one of the fol-
lowing: decrease in blood pressure ≥20 mmHg; need to start or increase vaso-
pressor infusion by 20%; decrease of haemoglobin ≥20 g/L; transfusion of ≥2 
units of red blood cells) occurs in around 2% of patients (Krag et al., 2015, 
2018). The main risk factors for GI bleeding include co-existing severe di-
seases, liver failure and coagulopathy (Krag et al., 2015).  While use of proton 
pump inhibitors in critically ill patients is associated with less frequent GI 
bleeding (2.5 vs 4.2%), there seems to be no effect on outcomes (a composite of 
clinically important gastrointestinal bleeding, pneumonia, Clostridium difficile 
infection, or myocardial ischaemia) (Krag et al., 2018). Accordingly, recent 
guidelines suggest limiting GI bleeding prophylaxis in the ICU to patients with 
the highest risk of bleeding (Ye et al., 2020). 
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Paralysis of the lower GI tract (paralytic ileus) refers to the inability of the 
bowel to pass stool due to impaired peristalsis (Reintam Blaser et al., 2012). In 
the absence of a mechanical obstruction, it can be diagnosed if stool is not 
passed for three or more consecutive days. Paralytic ileus affects 13–17% of 
patients undergoing major abdominal surgery (S. Iyer et al., 2009; Mogha-
damyeghaneh et al., 2016). Prolonged paralysis of the lower GI tract is seen in 
sedated and mechanically ventilated patients and those with increased intra-
cranial or intra-abdominal pressure (IAP), infections and sepsis, fluid overload 
and use of catecholamine drugs (Fruhwald et al., 2008). Bowel paralysis may 
lead to bowel distension, the most severe form being acute colonic pseudo-ob-
struction, known as Ogilvie’s syndrome (Ladopoulos et al., 2018). This synd-
rome is characterized by impaired colonic propulsion, which may resemble 
intestinal obstruction, but a mechanical cause is absent (Ladopoulos et al., 
2018). 
 
Bowel dilatation is defined as an increase in the diameter of the colon over 6 cm 
(greater than 9 cm for caecum) or the small bowel over 3 cm, diagnosed either 
on plain abdominal X-ray or computed tomography scan (Nicolaou et al., 2005; 
Krajewski et al., 2009). The most severe forms of  bowel dilatation without 
obstruction are Ogilvie’s syndrome and toxic megacolon(Reintam Blaser et al., 
2015b). Ogilvie’s syndrome is rare, occurring in 0.1% of ICU admissions (Ross 
et al., 2016), but carries a significant risk of colonic ischaemia and mortality of 
40% if ischaemia and/or perforation of the bowel occurs (Wells et al., 2017). 
Ogilvie’s syndrome has been associated with a variety of acute clinical condi-
tions including medical and both abdominal and other surgical pathologies, but 
affects predominantly patients with chronic comorbidities and the elderly 
(Wells et al., 2017).  
 
Abdominal distension is a sign arising from increased intra-abdominal volume, 
not necessarily related to a gastrointestinal pathology. With no uniform defini-
tion, it can be recognised as an increase in the sagittal diameter of the abdomen 
such that the anterior face of the abdomen extends higher than the imaginary 
line from the xiphoid process to the symphysis pubis in a supine patient 
(Reintam Blaser et al., 2015b). Causes may among others include ascites, bowel 
oedema or dilatation due to paralysis or obstruction (Reintam Blaser et al., 
2015b). Being a general and nonspecific sign, abdominal distension should 
warrant further investigation toward its causes. Abdominal distension may point 
to the presence of intra-abdominal hypertension (Reintam Blaser et al., 2015b). 
 
Intermittent assessment of gastric residual volume is frequently used to guide 
enteral nutrition and assess its tolerance. The rationale of this practice lies in the 
acknowledgement that gastric emptying is often delayed in critically ill patients 
(Ladopoulos et al., 2018), resulting in large gastric volumes that may subject the 
patient to vomiting or regurgitation and subsequent complications. Detecting 
large GRV would then allow administration of prokinetic drugs and decreasing 
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or reducing EN, possibly preventing harm. However, it has been questioned 
whether GRV may adequately reflect gastric emptying rate. A recent study in 
77 critically ill patients indeed established that GRV was moderately correlated 
to gastric emptying, assessed by 3-O-methylglucose pharmacokinetics, and that 
high GRV (>400 mL as one episode or two consecutive episodes of >250 mL) 
had a low specificity (47%), but high sensitivity (98%) in discriminating gastric 
emptying (Lew et al., 2021). The practice of assessing GRV is currently not 
standardised and highly variable in different centres, including differences in 
patient positioning, tube diameter, active aspiration vs passive outflow of 
gastric contents, discarding vs returning the gastric contents and other factors 
(Reintam Blaser et al., 2015b; Ladopoulos et al., 2018). In addition, variability 
exists in the interpretation of a given GRV, highlighted by a recent systematic 
review demonstrating that across 63 studies, the threshold for a large GRV 
ranged from 75 to 500 mL on a single measurement (median 250 mL) or 250 to 
1000 mL during a 24 hour period (Reintam Blaser et al., 2014b). The ESICM 
Working Group on Abdominal Problems proposes to consider GRV increased if 
a single volume exceeds 200 mL (Reintam Blaser et al., 2012). Even though 
single measurement values above 200 mL are abnormal, pausing EN is not 
necessary based solely on a 200–500 mL single GRV (Reintam Blaser et al., 
2012). In recent decades, the practice of measuring GRV through stopping EN 
and allowing for outflow of gastric contents has been subject to criticism. 
Several studies have suggested that measuring GRV with this method is 
associated with decreased nutrient delivery (Villet et al., 2005; Poulard et al., 
2010). A randomised controlled trial comparing a GRV threshold of 200 vs 500 
mL found that a use of a higher threshold was associated with more nutrients 
delivered during the first study week and a similar rate of complications (gastro-
intestinal complications, ICU-acquired pneumonia, duration of mechanical 
ventilation and ICU length of stay) (Montejo et al., 2010). Subsequently, a 
study among mechanically ventilated patients receiving EEN demonstrated that 
abandoning GRV measurements in mainly medical patients with already es-
tablished EN was not associated with an increased risk of ventilator-associated 
pneumonia compared to measuring GRV (Reignier et al., 2013). Similarly, a 
single-centre trial in medical ICU patients showed that not measuring GRV is 
associated with better nutrient delivery and a similar rate of gastric regurgitation 
as assessed by pH monitoring (Ozen et al., 2016). Current guidelines from the 
European Society for Clinical Nutrition and Metabolism support the use of 
GRV in assessing GI dysfunction and identifying intolerance to EN during 
initiation and progression of EN, stating that monitoring established EN with 
GRV measurements may not be necessary (Singer et al., 2019). The Society of 
Critical Care Medicine and American Society for Parenteral and Enteral 
Nutrition guidelines suggest not using GRV to monitor patients receiving EN 
(McClave et al., 2016). However, if GRV is used, all guidelines state that EN 
should be delayed if GRV is >500 mL (McClave et al., 2016; Reintam Blaser et 
al., 2017; Singer et al., 2019). 
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Motor function of the GI tract is traditionally assessed using auscultation of the 
abdomen. Absent peristalsis is assumed if no bowel sounds are heard at cautious 
auscultation, while hyperperistalsis is considered present if excessive bowel 
sounds are heard (Reintam Blaser et al., 2012). More recently, ultrasound has 
been used to evaluate gastric volume and emptying as well as intestinal dia-
meter, peristalsis and blood flow (Hamada et al., 2014; Haruma et al., 2008; 
Perez-Calatayud et al., 2018). Decreased bowel peristalsis is common among 
intensive care patients receiving analgosedation and catecholamine medications, 
with decreased or absent bowel sounds being present in half of the patients 
(Reintam Blaser et al., 2015b). Absence of bowel sounds has been shown to be 
independently associated to greater mortality rates (Reintam et al., 2008a; 
Reintam Blaser et al., 2013). Presence of excessive or tinkling bowel sounds 
may be a sign of bowel obstruction, a potentially life-threatening condition 
(Reintam Blaser et al., 2015b). 
 
Although the importance of GI symptoms has been shown, several areas of un-
certainty remain. It is not clear how to use GI symptoms in precise decision-
making regarding nutrition, in assessment of the GI function as well as 
evaluating the course and severity of multiple organ dysfunction. Further, it is 
not straightforward when can GI symptoms and IAH be considered simply 
epiphenomenons of critical illness and when could their treatment improve out-
comes. In study II, impact on outcomes of different etiologies of gastrointestinal 





2.3 Intra-abdominal hypertension 
Intra-abdominal pressure refers to the static pressure within the abdominal 
cavity. Relevant consensus definitions of the Abdominal Compartment Society 




Table 1. Consensus definitions of the World Society of the Abdominal Compartment 
Syndrome (Kirkpatrick et al., 2013) 
1 IAP is the steady-state pressure concealed within the abdominal cavity 
2 The reference standard for intermittent IAP measurements is via the bladder with 
a maximal instillation volume of 25 mL of sterile saline 
3 IAP should be expressed in mmHg and measured at end-expiration in the supine 
position after ensuring that abdominal muscle contractions are absent and with 
the transducer zeroed at the level of the midaxillary line 
4 IAP is approximately 5–7 mmHg in critically ill adults 
5 IAH is defined by a sustained or repeated pathological elevation in IAP ≥ 12 
mmHg 
6 ACS is defined as a sustained IAP > 20 mmHg (with or without an APP < 60 
mmHg) that is associated with new organ dysfunction/failure 
7 IAH is graded as follows 
 Grade I, IAP 12–15 mmHg 
 Grade II, IAP 16–20 mmHg 
 Grade III, IAP 21–25 mmHg 
 Grade IV, IAP > 25 mmHg 
8 Primary IAH or ACS is a condition associated with injury or disease in the 
abdominopelvic region that frequently requires early surgical or interventional 
radiological intervention 
9 Secondary IAH or ACS refers to conditions that do not originate from the 
abdominopelvic region 
10 Recurrent IAH or ACS refers to the condition in which IAH or ACS redevelops 
following previous surgical or medical treatment of primary or secondary IAH 
or ACS 
11 APP = MAP − IAP 
12 A polycompartment syndrome is a condition where two or more anatomical 
compartments have elevated compartmental pressures 
13 Abdominal compliance is a measure of the ease of abdominal expansion, which 
is determined by the elasticity of the abdominal wall and diaphragm. It should be 
expressed as the change in intra-abdominal volume per change in IAP 
14 The open abdomen is one that requires a temporary abdominal closure due to the 
skin and fascia not being closed after laparotomy 
15 Lateralization of the abdominal wall is the phenomenon where the musculature 
and fascia of the abdominal wall, most exemplified by the rectus abdominus 
muscles and their enveloping fascia, move laterally away from the midline with 
time 
IAP – intra-abdominal pressure; IAH – intra-abdominal hypertension; ACS – 
abdominal compartment syndrome; APP – abdominal perfusion pressure; MAP – mean 
arterial pressure. 
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Intra-abdominal hypertension occurs in 40–50% of intensive care patients (D. 
Iyer et al., 2014; Murphy et al., 2018; Reintam Blaser et al., 2019). Mortality 
increases with increasing grade of severity, and the most severe form of IAH, 
ACS carries a mortality rate of 75–90% (D. Iyer et al., 2014; Murphy et al., 
2018; Reintam Blaser et al., 2019). 
IAP can increase as a result of either an increased intra-abdominal volume, a 
decreased abdominal compliance, or both (Reintam Blaser et al., 2015a). Relevant 
causes for increased intra-abdominal volume in critically ill patients include intra- 
or extraluminal gas or fluid (e.g., bowel obstruction, ascites, pneumoperitoneum), 
tissue oedema (e.g., abdominal inflammation or infection, fluid resuscitation) or 
solids such as fat, tumour or a pregnant uterus. Abdominal compliance influences 
the extent of increase in IAP in response to addition of a given intra-abdominal 
volume: with decreased compliance, a lower amount of added volume causes a 
greater increase in IAP (Reintam Blaser et al., 2015a). A low abdominal com-
pliance cannot be measured at the bedside, but must be suspected in pathologies 
and conditions involving the abdominal wall, e.g. severe burn injuries, external 
constraints, previous abdominal surgery and massive fluid resuscitation with 
capillary leak (Reintam Blaser et al., 2015a). 
Elevated IAP impairs the function of many organs, both close and distant. 
The diaphragm is displaced cephalad, causing compression of the thoracic 
organs, notably the lungs and the heart. Compression of the lungs provokes ate-
lectasis, resulting in worsened intrapulmonary blood shunting with hypoxemia 
and hypercapnia, and reduced lung compliance (Obeid et al., 1995; Ridings et 
al., 1995) causing an increased work of breathing. Compression of the heart and 
the inferior vena cava is associated with decreased venous return and cardiac 
filling, leading to low cardiac output (Cheatham, 2009). Renal perfusion is 
reduced by compression of the renal vasculature, with ensuing oliguria and 
acute renal failure (Cheatham, 2009; Candan et al., 2020). Increased IAP likely 
impairs hepatic perfusion and/or function, assessed by plasma disappearance 
rate of indocyanine green (Malbrain et al., 2012). Abdominal wall muscle tissue 
ischaemia may occur already during short periods of modestly increased IAP of 
12‒13 mmHg (Maddison et al., 2012). In animal models, intra-abdominal 
hypertension from 15 mmHg has been shown to cause ischaemia of the small 
and large bowel resulting in bacterial translocation (Sertaridou et al., 2015).  
The exact IAP value that should be considered abnormal and define IAH has 
been subject to debate for some time. An early classification was proposed by 
Burch and colleagues, with IAH grade I corresponding to 7.5‒11 mmHg, based 
on physiological alterations becoming evident at these levels (Burch et al., 
1996). The current IAH threshold of 12 mmHg originates from the first con-
sensus definitions of the World Society of Abdominal Compartment Society, 
which took into account a large amount of accumulated data demonstrating that 
IAP as low as 10-15 mmHg may have negative effects on organ functions 
(Malbrain et al., 2006).  
Abdominal compartment syndrome refers to a situation where reductions in 
organ blood flows due to increased IAP leads to organ failure(s). In addition to 
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organs in the abdominal cavity, a polycompartment syndrome is recognized, in 
which the head, chest and extremity compartments are affected as a result of in-
creased IAP (Malbrain et al., 2014). This concept may involve both worsening 
of a primary injury in another compartment (e.g. traumatic brain injury) or a 
newly developing, secondary injury in a previously uninjured compartment (e.g. 
lower limbs) due to increased pressure in the abdomen (Malbrain et al., 2014). 
The associations between IAH and GI symptoms and enteral nutrition have 
been investigated in few studies. Observations in intensive care patients suggest 
that majority of patients with IAH also experience GI symptoms, and IAH of 
higher grade of severity is associated with more simultaneous GI symptoms 
(Reintam Blaser et al., 2011a). Occurrence of IAH and GI symptoms together is 
frequent (36%) and associated with worse outcomes than occurrence of either 
IAH or GI symptoms or absence of both either (Reintam Blaser et al., 2011a). 
Likewise, simultaneously occurring IAH and FI have been shown to be as-
sociated with worst outcomes (Reintam et al., 2008a). In a study randomizing 
patients with severe acute pancreatitis to early (within 48 hours) or delayed 
(from the 8th day) postpyloric EN, feeding intolerance was significantly more 
frequent in patients with early EEN, although no difference in the incidence of 
IAH was seen between the groups and surprisingly a trend towards less IAH 
was observed in those receiving EEN (Sun et al., 2013). In patients with IAP 
≥15 mmHg, the incidence of FI during the first week was significantly higher 
compared to patients with IAP <15 mmHg (91% vs 45%) (Sun et al., 2013). In 
a prospective observational study involving 247 critically ill patients, it was 
shown that IAH frequently precedes development of FI, but no cut-off value for 
IAP to predict FI could be determined (Bordejé et al., 2019). 
It is universally accepted that if IAH causes organ failure(s), ACS is to be 
diagnosed and treated. However, it is still not clear whether it is beneficial to 
intervene in case of mild to moderate increases of IAP. Previously, conflicting 
findings about the association between IAH as a yes-no phenomenon and 
mortality have been shown (Kim et al., 2012). However, more recent studies 
demonstrate better outcomes in those with lower and worse in those with higher 
grades of IAH (D. Iyer et al., 2014; Murphy et al., 2018; Reintam Blaser et al., 
2019). Still, the causality of such associations and whether outcomes can be 
improved with treatment of IAH, remain unanswered without randomised 
studies evaluating the effect of different strategies in treating mild to moderate 
IAH.  
Medical or minimally invasive treatment options are the first line in the 
management of IAH to prevent progression to ACS. Surgical decompression of 
the abdomen is often necessary in ACS and carries a high risk of complications; 
therefore, it would be desirable to avoid situations where it is inevitable. 
Decompressive laparotomy is recommended in ACS when medical manage-
ment fails (Kirkpatrick et al., 2013). Management of ACS with the emphasis on 




Nonsurgical management of IAH 
Management of IAH is aimed at reducing intra-abdominal volume, improving 
abdominal compliance and optimizing organ perfusion (Kirkpatrick et al., 
2013). For example, evacuation of intraluminal fluid or gas may be achieved 
using nasogastric drainage in patients with bowel obstruction or ileus and using 
a rectal tube in patients suffering from acute colonic pseudo-obstruction, while 
abdominal compliance may be improved using neuromuscular blockade or anal-
gesia and sedation (Kirkpatrick et al., 2013). However, the existing evidence is 
scarce and its quality low. Accordingly, most treatment options of IAH are 
either suggested with very low evidence or no recommendation could be made 
(Kirkpatrick et al., 2013).  Therefore, new knowledge on the effectiveness of 
different proposed medical management options is essential. The impact and 
side effects of deepening of sedation as a mode of treatment of IAH are eva-
luated in study III. 
 
 
2.4 Biomarkers of intestinal function and damage 
Currently, there are no biomarkers in everyday clinical use that could help diag-
nose or manage Gl problems in intensive care patients. Such biomarkers would be 
very valuable to help make the assessment of the GI function more objective. 
Several potential candidates have been studied during the last years, with good 
pathophysiological rationale suggesting further investigations into some of them. 
Citrulline has been proposed as a marker of intestinal function while intestinal 
fatty acid-binding protein (I-FABP) is considered a biomarker of intestinal 
damage. The most important aspects of these biomarkers are described below, 
with a more detailed overview given in Paper VII. Other biomarkers reflecting 
gut injury/ischaemia, discussed below in short detail, include ileal lipid binding 
protein, D-lactate, ischaemia modified albumin, α-glutathione S-transferase and 
the smooth-muscle protein of 22 kDa. Ileal lipid binding protein is a cytosolic 
protein present specifically in the epithelial cells of the ileum, being responsible 
for the transport of bile acids. Similar to I-FABP, it is released to circulation in 
case of intestinal hypoperfusion and subsequent loss of cell membrane integrity 
(van Wijck et al., 2011). D-lactate is an isomer of lactate which is present in 
only low concentrations in human blood, originating from intestinal bacterial 
metabolism mostly in the large intestine and some foods. Alteration of mucosal 
integrity due to intestinal ischaemia has been proposed as a mechanism for in-
creased D-lactate concentrations in blood (Montagnana et al., 2018). The metal 
binding capacity of human albumin (ischaemia modified albumin) is easily 
measured and is known to decrease in acute hypoxic conditions such as acute 
coronary syndrome, stroke, skeletal muscle ischaemia, but also acute mesenteric 
ischaemia (Montagnana et al., 2018). α-glutathione S-transferase is another 
biomarker of oxidative stress, but also lacks specificity, being present in both 
intestinal and hepatic cells (Montagnana et al., 2018). Smooth-muscle protein of 
22 kDa is involved in the maturation of smooth muscle cells and is abundantly 
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expressed in case of smooth muscle injury, e.g. a transmural intestinal ischae-
mic injury (Montagnana et al., 2018). A recent systematic review and meta-
analysis evaluating the diagnostic accuracy of the aforementioned biomarkers, 
excluding smooth-muscle protein of 22 kDa, found that highest specificity for 
acute mesenteric ischaemia was achieved with I-FABP (91%) and ischaemia 




Citrulline is a non-protein amino acid which is synthesised in many tissues of 
the human body, but the circulating citrulline originates almost exclusively from 
the gut (Curis et al., 2005). It is produced from glutamine in mature enterocytes 
of the small bowel and after being released in the circulation, is taken up and 
metabolised in the kidneys to arginine (Curis et al., 2005), being an important 
source of the latter. Therefore, citrulline plasma concentration reflects a balance 
between synthesis in the gut and uptake in the kidneys. In health, citrulline 
plasma concentration is about 40 µmol/L , while 20 µmol/L  seems to be the 
most frequent cut-off between low and normal values in studies involving 
critically ill patients (Fragkos & Forbes, 2018; Papadia et al., 2018). However, 
some authors argue that a cut-off value for “normal” citrulline likely does not 
exist in critically ill patients due to a variety of confounders and that it may be 
appropriate to interpret values of 10‒20 µmol/L as a grey area (Piton & Ca-
pellier, 2015). 
Plasma citrulline concentrations have been shown to be strongly correlated 
to the remaining small bowel length in patients with short bowel syndrome 
(Fragkos & Forbes, 2018), associating citrulline with bowel mass. Increasing 
data suggests that the same may be true for bowel function. Meta-analysis of 
studies evaluating the association of citrulline levels with intestinal absorption 
shows a moderate positive correlation (Fragkos & Forbes, 2018). Further, 
citrulline is negatively correlated with severity of disease in enteropathies (e.g. 
coeliac disease, mucositis, acute rejection in transplantation and others) (Frag-
kos & Forbes, 2018), while treatment of patients with short bowel syndrome 
with teduglutide, a glucagon-like peptide-2 analogue which promotes mucosal 
growth, is associated with an increase in citrulline levels (Fragkos & Forbes, 
2018). The aforementioned findings suggest that citrulline may be associated 
not only with enterocyte mass but also function, justifying studies in intensive 
care patients, in whom predominantly the function of enterocytes may be 
impaired in a variety of conditions. 
Among critically ill patients, low levels of citrulline have been described in 
subsets of patients with cardiac arrest (Grimaldi et al., 2013; Piton et al., 2015) 
and septic shock (Crenn et al., 2014; Luiking et al., 2009) as well as in the 
general ICU population (Piton et al., 2010; Noordally et al., 2012; Piton et al., 
2013; Piton, Cypriani, et al., 2015; Poole et al., 2016; Piton et al., 2019). 
Associations between low citrulline levels and poor outcomes have been 
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reported in several studies (Piton, Belin, et al., 2015; Piton et al., 2010, 2013). 
Proposed mechanisms for low citrulline values in critically ill patients include 
intestinal hypoperfusion resulting in mucosal ischaemia and reduced intestinal 
villi length and sepsis-associated glutamine deficiency and reduced de novo 
citrulline synthesis (Piton & Capellier, 2016).  
In studies investigating the temporal dynamics of citrulline in ICU patients 
(Piton et al., 2010; Grimaldi et al., 2013; Piton et al., 2019), a common finding 
is a U-shaped curve – an initial decrease in the first few post-admission days is 
followed by an increase by the end of the first week. It has been discussed that 
such dynamics may correspond to an initial period of damage followed by a 
period of renewal of enterocytes (Piton & Capellier, 2016; Piton et al., 2019). 
Low values of citrulline have also been described in critically ill patients 
with clinically apparent GI dysfunction. Fagoni et al. demonstrated that gastro-
intestinal failure, defined as the concomitant presence of IAH and feeding 
intolerance (Reintam et al., 2008a), was associated with very low citrulline 
values of less than 10 µmol/L. Noordally et al. reported low citrulline values of 
< 15 µmol/L in patients with intestinal dysfunction, defined as presence of 
feeding intolerance, ileus, diarrhoea or GI bleeding (Noordally et al., 2012). 
Yet, in a small observational study investigating glucose absorption in critically 
ill patients, no correlation between fasting citrulline concentration and sub-
sequent absorption of glucose could be demonstrated (Poole et al., 2016). 
Attention should also be paid on renal function when interpreting values of 
citrulline in critically ill patients. As the vast majority of citrulline is degraded 
in the kidneys, chronic renal dysfunction is associated with higher values of 
citrulline (Lau et al., 2000; Pironi, Guidetti, et al., 2015). Higher values of 
citrulline compared to controls with normal renal function have been shown if 
creatinine clearance is less than 50 mL/min (Pironi, Guidetti, et al., 2015). 
Several studies investigating citrulline in critically ill patients have a priori ex-
cluded those with chronic renal failure. Yet, in studies reporting citrulline in 
patients with acute renal failure, no differences to controls have been demon-
strated (Noordally et al., 2012; Piton et al., 2010; Grimaldi et al., 2013). 
 
 
2.4.2. Intestinal fatty acid-binding protein 
I-FABP, also known as FABP2, is a small protein in the family of fatty acid 
binding proteins which participate in the uptake, metabolism and transport of 
long-chain fatty acids (Smathers & Petersen, 2011). This protein is found 
exclusively in mature enterocytes of the small and large intestine – mainly in 
the duodenum and jejunum and much less in the ileum and colon (Pelsers et al., 
2005). The normal life cycle of an enterocyte ends with apoptosis and shedding 
into the intestinal lumen with no release of intracellular contents. Accordingly, 
the levels of I-FABP in plasma are very low or undetectable in healthy 
individuals (Pelsers et al., 2005; de Haan et al., 2009). Owing to a low mole-
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cular weight, circulating fatty acid binding proteins are rapidly cleared via 
kidneys with an elimination half-life of 11 minutes (van de Poll et al., 2007).  
When enterocyte membrane is disrupted, I-FABP is released into the 
circulation (Schellekens et al., 2014). As mature enterocytes are present at the tips 
of intestinal villi, a location especially vulnerable to ischaemia, I-FABP has been 
of great interest as a marker of ischaemic damage to the intestinal epithelium. 
Elevated I-FABP plasma levels have been demonstrated in various setting and 
degrees of intestinal ischaemia, Including intense exercise in healthy adults 
(Edinburgh et al., 2018; Karhu et al., 2017), major non-abdominal surgery 
(Derikx et al., 2008; Habes et al., 2017; Zou et al., 2018), trauma (de Haan et al., 
2009; Timmermans et al., 2015), acute mesenteric ischaemia (Cronk et al., 2006; 
Kanda et al., 2011; Vermeulen Windsant et al., 2012), cardiac arrest (Grimaldi et 
al., 2013; Piton et al., 2015) and a variety of other conditions.  
I-FABP appears in the circulation rapidly, within 30 minutes after onset of 
small bowel ischaemia (Schellekens et al., 2014), and disappears within 120 mi-
nutes of reperfusion (Schellekens et al., 2017). However, in critically ill pa-
tients, the symptoms of bowel ischaemia may go unnoticed for a while due to 
analgesia and sedation. In a pragmatic study involving critically ill patients, the 
suspicion of bowel ischaemia arose and samples were collected hours after a 
potential triggering event, and I-FABP plasma values did not differ between 
those who developed small bowel ischaemia vs those who did not (Ludewig et 
al., 2017). It was argued that irreversible ischaemia causing no wash-out of I-
FABP may explain the lack of I-FABP increase in patients with bowel ischae-
mia (Ludewig et al., 2017). 
A relationship with elevated plasma I-FABP values and poor outcomes has 
been demonstrated. In studies by Piton et al. involving critically ill patients,  
admission I-FABP values greater than 355 pg/mL (Piton et al., 2013) and  
524 pg/mL (Piton, Cypriani, et al., 2015) were independently associated with 
higher mortality at 28 days. In patients resuscitated from cardiac arrest, admis-
sion I-FABP value greater than 260 pg/mL was independently associated with a 
poor neurological outcome (OR 13.6, 95% CI 1.4–129) (Piton, Belin, et al., 
2015). Additionally, post-resuscitation admission values of I-FABP were positi-
vely correlated with endotoxin levels, signalling gut barrier failure due to is-
chaemia (Grimaldi et al., 2013). 
Renal failure delays clearance of I-FABP from the plasma (Kittaka et al., 
2014), with a twofold increase seen in patients with end-stage renal failure and 
normalization of plasma levels after haemodialysis (Okada et al., 2018). 
An important consideration when comparing the studies is the measurement 
technique used for I-FABP and its reference values. Commonly enzyme-linked 
immunosorbent assay (ELISA) is used. Several kits are available that demon-
strate greater than 100-fold inter-assay differences in I-FABP values both in 
controls as well as in patients with acute mesenteric ischaemia (Treskes et al., 
2017). Therefore, values between studies using different measurement techni-
ques are not interchangeable and dynamics rather than absolute values can be 
compared. 
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In summary, evidence from settings outside intensive care support the use of 
citrulline and I-FABP as markers of enterocyte function and damage, respec-
tively. Several confounding factors complicate the interpretation of the values 
of the biomarkers. Associations of low citrulline and high I-FABP values with 
outcome of critically ill patients are well described, however, the role of the bio-
markers in assessing the functioning of the GI tract and guiding of nutrition is 
less clear.  
In this dissertation we explore whether citrulline and I-FABP could be used 
in assessment of GI dysfunction as a part of multiple organ dysfunction and in 
guiding decision-making in enteral nutrition. In study IV, the contribution of the 
biomarkers towards a score quantifying gastrointestinal dysfunction is assessed. 
In study V, the dynamics of citrulline and I-FABP are investigated in relation to 




2.5 Gastrointestinal dysfunction and failure 
The GI tract has several functions, including digestion and absorption of nut-
rients and water, barrier, endocrine and immune functions, while adequate per-
fusion, secretion, motility and coordinated gut-microbiome interactions are ne-
cessary for normal functioning (Reintam Blaser et al., 2012). However, it is not 
easy to identify normal GI function in the critically ill. Some aspects of the 
adaptation of the GI tract to critical illness have been described above, including 
loss of appetite, anorexia and decreased motility. Even though no unified defini-
tion of normal functioning of the GI tract in critical illness exists, the recog-
nition and diagnosing of abnormal function is necessary for both clinical and 
research use to assess and manage gastrointestinal problems in intensive care 
patients.  
Clinical assessment has remained the main method to monitor GI function in 
the critically ill. No imaging strategy, biomarker nor method to assess absorp-
tion or barrier function has been sufficiently validated or is available for clinical 
use. Consequently, previous attempts at quantifying GI dysfunction in intensive 
care patients have mostly centred around clinical assessment of gastrointestinal 
or abdominal signs and symptoms. Previous attempts at defining GI dysfunction 
or failure, notably varying, are shown in Table 2 (adapted from (Reintam Blaser 
et al., 2016). There is also significant inconsistency in the terminology of such 
attempts, with the terms “dysfunction” and “failure” both having been used to 
represent a continuum of abnormal functioning, but also a yes/no-phenomenon. 
In our opinion, the term “dysfunction” would be appropriate to describe the 
continuum of changes, while “failure” would be a dichotomous characteristic of 












































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Below, a few approaches laying the groundwork to the research in the present 
dissertation are described in more detail. 
In 2008, the GIF score was created on the basis of feeding intolerance and 
intra-abdominal hypertension (Reintam et al., 2008a). FI was defined as the need 
to discontinue EN due to repeated or profuse vomiting, high GRV, ileus, severe 
diarrhoea, abdominal pain or distension. FI was not considered present if feeding 
was not undertaken during the first 3 days after abdominal surgery. Among 264 
mechanically ventilated patients admitted consecutively to a single study centre, 
with an ICU length of stay of at least one day, FI developed in 58% and IAH in 
27% of patients. A clinical score with 4 grades of severity was created, with the 
following gradation: 0 – normal gastrointestinal function; 1 – enteral feeding 
possible, but achieving <50% of calculated needs or no feeding during 3 days 
after abdominal surgery; 2 – FI or IAH; 3 – FI and IAH; 4 – abdominal com-
partment syndrome. The average GIF score during the first 3 days of ICU ap-
peared as an independent risk factor for ICU mortality and slightly improved the 
ability to predict mortality of the Sequential Organ Failure Assessment (SOFA) 
score. Nevertheless, while the GIF score can be easily assessed using readily 
available clinical data, major limitations include the subjective nature of deter-
mining FI and the fact that the score does not reflect a continuum of function. 
In a subsequent attempt to create a GI dysfunction score able to predict out-
come, 377 mechanically ventilated adult patients from 40 ICUs were included 
in a prospective study collecting data on prespecified GI symptoms (absent 
bowel sounds, vomiting/regurgitation, GRV, diarrhoea, bowel distension, GI 
bleeding), feeding and IAH (Reintam Blaser et al., 2013). Based on daily com-
parisons between survivors and nonsurvivors with different number of GI 
symptoms, a cut-off for GI failure was identified at the presence of 3 concomi-
tant symptoms in one day. GIF diagnosed by the presence of 3 symptoms 
occurred in 6.4% of patients and if present on admission day, was associated 
with a threefold independent increase in mortality. In creating a GI failure score, 
neither feeding-related variables nor IAH improved the predictive ability of the 
score. Accordingly, a score, named similarly the GIF score, was proposed based 
on 6 aforementioned GI symptoms, where the severity gradation was as 
follows: 0 – no GI symptoms; 1 – 1 symptom; 2 – 2 symptoms; 3 – 3 symp-
toms; 4 – ≥4 symptoms. Even though an increasing GIF score was associated 
with a higher mortality rate, the score was not able to add any value to the 
SOFA score in terms of mortality prediction. It was argued that this may be ex-
plained with GIF occurring secondary to other organ failures, already included 
in the SOFA score, and not as a primary organ failure. 
In 2012, the Working Group on Abdominal Problems of the ESICM pro-
duced a consensus document unifying the terminology and definitions of acute 
GI failure and GI symptoms (Reintam Blaser et al., 2012). A conceptual model 
of gastrointestinal dysfunction was proposed in the form of the Acute Gastro-
intestinal Injury (AGI) grading, which included five degrees of severity,  
with AGI 0 corresponding to normal functioning of the GI tract; AGI 1 – risk;  
30 
AGI 2 – GI dysfunction; AGI 3 – GI failure; AGI 4 – life-threatening condition 
due AGI causing distant organ failure (Table 3).  
 
 
Table 3. Acute Gastrointestinal Injury grades (Reintam Blaser et al., 2012).  
AGI 0 Definition: GI system appears to function normally, no signs of GI dysfunction 
AGI I Definition: GI symptoms related to a known cause and perceived as transient. 
Rationale: Condition is clinically seen as occurrence of GI symptoms after an 
insult, which expectedly has temporary and self-limiting nature. 
Examples: 
- Postoperative nausea or vomiting during the first days after abdominal surgery 
- Postoperative absence of bowel sounds 
- Diminished bowel motility in the early phase of shock 
AGI II Definition: GI symptoms requiring therapeutic interventions for achievement of 
nutrient and fluid requirements. 
Rationale: This condition occurs without previous GI interventions or is more 
severe than might be expected in relation to the course of preceding abdominal 
procedures. No changes in general condition of the patient related to GI problems. 
Examples: 
- Gastroparesis with high gastric residuals or reflux 
- Paralysis of the lower GI tract 
- Diarrhoea 
- Intra-abdominal hypertension (IAH) grade I (intra-abdominal pressure (IAP) 
12–15 mmHg) 
- Visible blood in gastric content or stool 
AGI III Definition: restoration of GI function is not achieved despite interventions and 
the general condition is not improving. 
Rationale: sustained intolerance to enteral feeding without improvement after 
treatment (e.g., erythromycin, postpyloric tube placement), leading to persistence 
or worsening of multiple organ dysfunction syndrome. 
Examples: 
- Despite treatment, feeding intolerance is persisting possibly associated with 
persistence or worsening of multiple organ dysfunction syndrome: 
- High gastric residuals 
- Persisting GI paralysis 
- Occurrence or worsening of bowel dilatation 
- Progression of IAH to grade II (IAP 15–20 mmHg) 
- Low abdominal perfusion pressure (APP) together with IAH (below 60 mmHg) 
AGI IV Definition: AGI has progressed to become directly and immediately life-
threatening, with worsening of multiple organ dysfunction syndrome and shock. 
Rationale: AGI has led to an acute critical deterioration of the general condition 
of the patient with distant organ dysfunction(s). 
Examples: 
- Bowel ischaemia with necrosis 
- GI bleeding leading to haemorrhagic shock 
- Ogilvie’s syndrome 
- Abdominal compartment syndrome (ACS) 
GI – gastrointestinal; IAH – intra-abdominal hypertension; IAP – intra-abdominal pres-
sure; APP – abdominal perfusion pressure; ACS – abdominal compartment syndrome.  
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Proposed for both clinical and research purposes, the AGI grading was initially 
developed based on expert opinion with no research directly backing its 
constitution. The AGI grading has later been externally validated regarding 
mortality in several studies (Hu et al., 2017; Zhang et al., 2018; Loudet et al., 
2020; Ding et al., 2020). Although performing well in clinical practice, impor-
tant limitations of the AGI grading include inability to apply it retrospectively, 
subjectivity and likely effect from other organ dysfunctions, elaborated further 
in the discussion section of this dissertation. 
Currently, no existing clinical score of GI dysfunction is perfect for both cli-
nical and research use. The main objective of the iSOFA project (study IV) was 
to create a new score to quantify GI dysfunction, based on a combination of GI 
symptoms, IAP and biomarkers.  
 
 
2.6. Summary of the review of the literature 
The importance of problems related to the GI tract in critically ill patients is 
increasingly recognised. The research in the field has greatly advanced in the 
last decades, allowing for development of wide-scoping societal guidelines in 
the areas of nutrition and intra-abdominal hypertension. Still, large areas of un-
certainty remain. Optimal targets of nutrition as well as the timing and mode to 
achieve them are a matter of debate. Unlike other organ systems, assessment of 
the functioning of the GI tract in everyday practice currently remains based on 
an unstructured evaluation of abdominal and GI symptoms, with only a few 
numerical values available. Further, while the importance of these symptoms is 
recognised, it is generally not clear whether, when and with which methods 
should they be attempted to be treated to achieve better outcomes for critically 
ill patients.  
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3. AIMS OF THE RESEARCH 
The studies in this dissertation were focused on the prescription and manage-
ment of enteral nutrition, the diagnosis and outcome of gastrointestinal dys-
function and the use of biomarkers to aid in the previous fields as well as the 
management of the closely related intra-abdominal hypertension and abdominal 
compartment syndrome.  
 
The specific aims were the following: 
1. To evaluate the effect of an enteral feeding protocol on nutritional provision, 
gastrointestinal symptoms and outcome in long-staying ICU patients (study I). 
2. To describe the prevalence and outcome of gastrointestinal failure, defined 
through the simultaneous occurrence of several GI symptoms, and to charac-
terise GIF according to its aetiology (study II).  
3. To evaluate the effectiveness and safety of deepening of sedation, a re-
commended treatment option of IAH, among mechanically ventilated inten-
sive care patients (study III).  
4. To create an objective and reproducible score for gastrointestinal dysfunc-
tion based on gastrointestinal and abdominal signs and symptoms as well as 
the biomarkers citrulline and I-FABP, and evaluate its ability to predict treat-
ment outcome (study IV).  
5. To evaluate the associations of the biomarkers citrulline and I-FABP with 
enteral nutrition (study V). 
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4. MATERIALS AND METHODS 
This dissertation is based on 5 original studies, including over 4500 ICU pa-
tients in total, the main characteristics of which are shown in Table 4. 
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ICU – intensive care unit; GIF – gastrointestinal failure; IAH – intra-abdominal 
hypertension; IAP – intra-abdominal hypertension; iSOFA – intestinal-specific organ 
failure assessment; I-FABP – intestinal fatty acid-binding protein; ACS – abdominal 
compartment syndrome.  
 
 
This research was supported by grants to the University of Tartu from the Ab-




The Research Ethics Committee of the University of Tartu approved the studies 
I (approval no. 258/T-6) and II (approval no. 264/T-4) with waived informed 
consent. Study III was approved by the Research Ethics Committee of the 
University of Tartu (approval nos. 260/T-8 and 289/T-27). Delayed informed 
consent was obtained from the patient or the next of kin and in case of refusal to 
participate in the study, collected data were discarded. The study is registered at 
ClinicalTrials.gov (NCT02944292). 
 
The iSOFA study (studies IV and V) was approved by the Research Ethics 
Committee of the University of Tartu (approval 265/M-28). Approval from the 




4.2. Patients and study design 
4.2.1 Enteral feeding protocol study (I) 
The study population consists of adult patients (≥18 years) who were treated for 
at least 7 consecutive days in the 1st ICU of the Tartu University Hospital, ex-
cluding readmissions. In a retrospective before-and-after study, the effects of 
implementing a nurse-driven enteral feeding protocol were evaluated. In 2013, a 
feeding protocol, constructed based on examples found in the literature, was 
implemented in the study unit (Figure 1). The Before group consists of eligible 
patients admitted to the ICU in years 2011 and 2012, while the After group 
includes patients admitted in years 2014 and 2015. The year 2013 was con-
sidered a period of adaptation to the feeding protocol. Nutrition of patients in 
the Before group was handled by intensive care physicians in a non-proto-
colised manner and nurses were responsible for the delivery of nutrients, while 
in years 2014 and 2015 the enteral feeding protocol was in everyday use. Adhe-
rence to the protocol was not assessed in the current study. Clinical characte-
ristics, nutritional and outcome data were compared between patients in the 





ICU – intensive care unit; PaO2 – partial pressure of oxygen in arterial blood; NG – 
nasogastric; GRV – gastric residual volume; GI – gastrointestinal; IAP – intra-
abdominal pressure. 
 





The feeding protocol draws attention to the possibility of enteral nutrition early 
after admission to ICU, also specifying situations where EN is to be delayed. 
The progression of feeding rate relies on the regularly measured GRV and GI 
symptoms, with a reduction or cessation of feeding in case of GI problems. If 
GRV is low and GI symptoms absent, a target rate of 70–80 ml/h is achieved by 
72–96 hours from the start of feeding. 
 
 
4.2.2. Gastrointestinal failure study (II) 
All adult patients, including readmissions, that were admitted to the 1st ICU of 
the Tartu University Hospital in years 2004–2015 were included in this study. 
GIF was defined as the simultaneous presence (during one day) of 3 or more 
gastrointestinal symptoms. According to its aetiology, GIF was divided into 
primary (GIF occurring in a patient with a GI pathology, including oesophageal, 
gastric, hepatic, pancreatic, biliary, small and large intestine sites of illness, 
trauma or surgery) and secondary (due to some other pathology). Clinical 
characteristics and treatment outcomes were compared between patients with 
and without GIF, and primary and secondary GIF. 
  
 
4.2.3. Intra-abdominal pressure and sedation study (III) 
Mechanically ventilated intensive care patients with intra-abdominal hyper-
tension, treated in adult ICUs of the Tartu University Hospital, were eligible for 
inclusion in this study. Exact inclusion and exclusion criteria are shown in 
Table 5. The effect of deepening of sedation on intra-abdominal pressure, 
haemodynamic and respiratory parameters was evaluated.  
 
 
Table 5. Inclusion and exclusion criteria.  
Inclusion criteria Exclusion criteria 
- Age ≥18 years - Contraindication to propofol 
- Use of invasive mechanical 
ventilation 
- Contraindication to measuring IAP in 
the supine position 
- Intra-abdominal pressure 12–20 
mmHg in at least 2 consecutive 
measurements within 12 hours 
- Ongoing high dose infusion of propofol 
(>4 mg/kg/h actual body weight) 
- Spontaneous respiratory rate ≥6 
breaths per minute 
- Other intervention planned to reduce 
IAP during anticipated study period 
- RASS 0…-4 points  








Figure 2. Study layout. 
 
 
To counteract the possible hypotension related to the intervention, a haemo-
dynamic management algorithm was in place with prompt administration of 
vasoactive therapy upon development of hypotension. Briefly, the general hypo-
tension trigger was MAP of 60 mmHg. In some patients, a higher threshold had 
been individually specified where clinically indicated (e.g., hypertension) out-
side of the study intervention. In these cases, the MAP goal was used as the 
hypotension trigger. If a patient developing hypotension was previously re-
ceiving noradrenaline, the infusion rate was increased in order to preserve MAP 
at >60 mmHg or above individual target. If a patient developing hypotension 
had not previously been receiving noradrenaline, intravenous boluses of nor-
adrenaline were given. If more than 3 boluses were needed, a continuous infu-
sion of noradrenaline was started to preserve the MAP above the target level. 
MAP was assessed throughout the study (not only at pre-specified time points) 
and if hypotension occurred, it was managed immediately. The dose of propofol 
was reduced by steps of 1 mg/kg/h if more than 0.2 mcg/kg/min (or an increase 
of more than that amount) of noradrenaline was needed to counteract hypo-
tension. If used, infusion rates of other vasoactive or inotropic drugs were left 
unchanged throughout the study intervention. The primary study outcome was 
IAP at 30 minutes of propofol infusion, secondary outcomes included changes 




4.2.4. iSOFA study (IV) and Enteral nutrition and  
biomarkers study (V) 
In the multicentre prospective observational study, consecutive adult patients 
admitted to the 11 participating ICUs in nine countries were included, excluding 
those with limitation of care present on ICU admission. Patients with no in-
formed consent and those readmitted after previously completing the observa-
tion period were also excluded. 
Part A of the study, comprising of clinical data collection, was conducted in 
all 11 study centres, while part B, where plasma citrulline and I-FABP were 
measured in addition, was carried out in 6 centres. Between 2015 and 2018, 
each study centre aimed to enrol at least 25 patients during a period of 2–4 con-
secutive weeks. The observation time for each patient was 7 days or until ICU 
discharge, whichever occurred earlier. Standard care was continued at all study 
sites. 
 
4.3. Data collection 
4.3.1. Enteral feeding protocol study (I) and  
Gastrointestinal failure study (II) 
Data were collected from an electronic database, used in 1st ICU of the Tartu 
University Hospital since January 1st, 2004. Data of all patients admitted to the 
study unit were entered into the database prospectively. Additional data re-
garding hospital-acquired infections and mortality were acquired from the hos-
pital’s Infection Control Department and the national Population Register, 
respectively. The following data were collected:  
 
Admission and outcome parameters 
These included patient age, sex, body mass index (BMI), a surgical or non-
surgical diagnostic category, admission after abdominal surgery, APACHE 
(Acute Physiology and Chronic Health Evaluation) II score, use of vasopressor 
or inotropic treatment and mechanical ventilation and presence of sepsis, severe 
sepsis or septic shock on admission to ICU. Outcome data were ICU length of 
stay and duration of mechanical ventilation, incidence of hospital-acquired 
infections (ventilator-associated pneumonia, blood stream infection, urinary 
tract infection, Clostridioides difficile infection) and mortality at ICU discharge 
and at 30, 60, 90 and 120 days.  
 
Daily data 
Documented gastrointestinal symptoms were the absence of bowel sounds, 
gastric residual volume, bowel distension, vomiting, GI bleeding, diarrhoea. 
The number of calories provided via the enteral and parenteral routes and the 




Absence of bowel sounds – as determined by an intensive care physician on 
auscultation.  
Gastric residual volumes were measured by pausing enteral nutrition for 30 
minutes, opening the nasogastric tube and allowing passive drainage for 30 
minutes. Frequency of GRV measurements was left at the discretion of the 
nurse and intensive care physician, but measured at least once a day from 2004 
to 2012, and based on the enteral feeding protocol from 2013 to 2015. For study 
II, a large GRV was considered present when the evacuated amount was >500 
mL in one day. Prior to implementing the feeding protocol in 2013, decisions 
regarding large GRV management were unstandardized, but from 2013 onwards 
were based on guidance from the feeding protocol (Figure 1). 
Bowel distension – radiologically confirmed dilatation of any bowel 
segment. 
Vomiting – Any amount of regurgitated gastric contents.  
GI bleeding – Presence of any visible amount of blood in stomach contents 
or stool. 
Diarrhoea – occurrence of liquid stools at least 3 times in one day.  
Energy requirement was calculated using a weight-based formula of 25 
kcal/kg (adjusted body weight) per day and assessed on day 4 and day 7. 
Overfeeding was defined as receiving more than 110% of calculated full energy 
requirement and underfeeding as receiving less than 80% of caloric needs via 
any route. Dextrose-based maintenance infusions were included in the calcu-
lations, whereas the nutrition value of propofol and citrate, used as anticoagu-
lation during renal replacement and plasma exchange therapies, was not 
considered. 
Sepsis was diagnosed according to the Sepsis-2 definitions (Levy et al., 
2003) that were in use at the time of conduction of studies I and II. Sepsis was 
diagnosed in a patient with a confirmed or suspected infection and at least 2 of 
the following criteria for systemic inflammatory response syndrome: leukopenia 
<4000/µL or leukocytosis >12000/µL or >10% of immature (band) forms; 
temperature >38 °C or <36 °C; heart rate >90 beats per minute; respiratory rate 
>20 breaths per minute, PaCO2 <32 mmHg or mechanical ventilation. Severe 
sepsis was defined as sepsis with at least 1 organ failure. Septic shock was 
defined as hypotension related to sepsis, persisting after adequate fluid replace-
ment and requiring vasopressor support.  
 
 
4.3.2. Intra-abdominal pressure and sedation study (III)  
Collected data included admission data (age, sex, weight, height, patient profile, 
principal pathology) and baseline characteristics (SOFA score, cumulative fluid 
balance, aetiology of IAH). Data documented at pre-specified time points 
during the intervention were intra-abdominal, mean arterial pressure (MAP) and 
abdominal perfusion pressure (APP), sedation depth according to Richmond 
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Agitation-Sedation Scale (RASS), the use and dose of vasoactive/inotropic 
medication(s), names and doses of sedative drug(s) and respiratory parameters 
(ventilation mode, spontaneous and total respiratory rate, peak and plateau pres-
sures, tidal volume).  
In the study units, intra-abdominal pressure is commonly measured at the 
discretion of the intensive care physicians and a manometric intravesical tech-
nique is used (UnoMeter AbdoPressure, Convatec, United Kingdom). In 
patients eligible to participate in the study (i.e., sustained intra-abdominal 
hypertension detected), an AbViser AutoValve IAP monitoring device (Con-
vatec, United Kingdom) was inserted and used to measure IAP during the study. 
This device was used owing to proven good reproducibility of its results, with 
an intra-observer variability of 0.57 mmHg (Kimball et al., 2007). IAP was 
measured with the patients lying supine with no head of bed elevation through-
out the intervention. The transducer was positioned at the mid-axillary line and 
an end-expiratory IAP value was recorded. Each measurement was performed 
using a 20 mL instillation of 0.9% sodium chloride solution at room tempe-
rature. This method is in accordance with the guidelines of the Abdominal 
Compartment Society (Kirkpatrick et al., 2013).   
 
 
4.3.3. iSOFA study (IV) and Enteral nutrition and  
biomarkers study (V) 
Daily data collection included documentation of gastrointestinal symptoms and 
abdominal signs, gastric residual volume, intra-abdominal pressure, data on 
feeding and use of prokinetic drugs and the SOFA sub-scores and evaluation of 
the Acute Gastrointestinal Injury grade (Reintam Blaser et al., 2012). GRV and 
IAP were measured only in patients in whom a nasogastric tube and an ind-
welling bladder catheter were used as a standard practice, respectively. 
In sites participating in part B of the study, blood samples were drawn for 
measurement of the amino acid citrulline and I-FABP immediately upon on 
admission to the ICU and thereafter daily in the morning for 7 days or until ICU 
discharge.  
Blood samples were collected into standard vacutainers containing EDTA, 
immediately cooled on ice and centrifuged at 4 °C to separate plasma. Plasma 
samples were stored at -80 °C at each study site. All samples were analysed at 
the Bioanalytical Facility of the University of East Anglia, Norwich, United 
Kingdom. Citrulline was measured using liquid chromatography – mass 
spectrometry following deproteinization of samples. The reference range for 
citrulline, obtained from healthy fasted adults, was 17–46 µmol/L. I-FABP was 





List of gastrointestinal symptoms and abdominal signs 
Vomiting/regurgitation, absent bowel sounds, diarrhoea, abdominal distension, 
GI bleeding, GI paralysis/dynamic ileus were defined according the recommen-
dations of the ESICM Working Group on Abdominal Problems, shown in the 
Review of the literature section of the dissertation (Reintam Blaser et al., 2012).  
Additionally, severe diarrhoea was diagnosed as liquid stools at least 5 times 
in one day or greater than 1000 mL per day if a stool collector was used.  
Gastrointestinal bleeding was further divided according to severity: not 
needing transfusion; needing transfusion; leading to haemorrhagic shock. 
Intra-abdominal hypertension was diagnosed if the mean IAP value of all 
measurements during one day was ≥12 mmHg. 
 
 
4.4. Statistical methods 
Statistical analyses were performed using SPSS Statistics (IBM Corp. IBM 
SPSS Statistics for Windows, Versions 23.0 and 25.0. Armonk, NY: IBM 
Corp.) and R (R Foundation for Statistical Computing, Vienna, Austria). 
Categorical variables were compared using the χ2 test for large or Fisher’s 
exact test for small samples. Continuous variables were compared using the 
Wilcoxon-Mann-Whitney test for non-normally distributed data and the t-test 
for data with normal distribution.  
Univariate analysis was used to identify risk factors for insufficient EN 
(study I) and IAP decrease in response to deepening of sedation (study III). 
Variables with P<0.2 were entered into multiple logistic regression model to 
identify independent risk factors for respective outcomes. In study II, SOFA 
sub-scores and the number of GI symptoms were entered into multiple logistic 
regression models to comparatively evaluate the variables’ ability to predict 
mortality.  
Kaplan-Meier curve and log-rank test were used to compare survival of 
patients with and without GIF (study II).  
Linear mixed models (LMM) were used to describe and compare dynamics 
of citrulline and I-FABP over time and between patient groups (study V). The 
biomarkers were used as outcomes, with log-transformation necessary to 
achieve a normal distribution of residuals. Time, group and interaction between 
time and group were entered to the models as fixed effects, with various 
covariance structures tested to achieve an optimal fitness.  
In developing the Gastrointestinal Dysfunction Score (GIDS) in the iSOFA 
study (IV), first the descriptive AGI grading and thereafter single clinical 
symptoms and biomarkers were tested for 28- and 90-day mortality prediction 
using time-dependent Cox proportional hazard regression models. The descrip-
tive AGI was able to independently predict mortality, while biomarkers were 
not. Therefore, the approach to construct the new score using a combination of 
symptoms to predict the original descriptive AGI grading was chosen. Different 
types of models were fitted to understand how different GI symptoms 
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discriminate between different AGI grades. To facilitate categorization, the 
continuous variables of intra-abdominal pressure and gastric residual volume 
were dichotomised based on ROC-curve analyses. GI symptoms and conditions 
identifying a less or more severe condition were identified. Based on evidence 
that higher AGI grades also corresponded to a greater number of symptoms, the 
number of symptoms was also considered relevant in creating the score. The 
most severe category (4) was defined differently from others, based on the ratio-
nale that in the descriptive AGI grading, the most severe category is defined as 
a life-threating condition. Accordingly, three conditions were classified as 
GIDS 4: GI bleeding causing haemorrhagic shock, mesenteric ischaemia, abdo-
minal compartment syndrome. Each respective case of this highest score was 
carefully identified from the database through a case-by-case assessment by 3 
co-authors independently. Thereafter through the sequential testing of several 
test-scores against the descriptive AGI grading, the GIDS was developed. After 
constructing the score with clinical data, addition of biomarkers citrulline and I-
FABP to the score was tested using different cut-offs based on the literature and 
biomarker reference values. The C-statistic was used to describe the predictive 
capability of the scores and their combinations. To reduce the effect of different 
study sites, the Cox regression models are reported centre stratified.  
 
 
4.4.1. Sample size calculations 
4.4.1.1. Intra-abdominal pressure and sedation study (III) 
With the assumption of normally distributed data, the t-test was to be used to 
test the primary hypothesis that deepening of sedation reduces IAP by 3 mmHg. 
This effect size was chosen as it was considered to be clinically relevant and 
achievable. Assuming that 1) standard deviation was 6 mmHg at both time 
points (baseline and at 30 minutes of propofol infusion), based on a previous 
study (Reintam A et al., 2008); 2) the between-group correlation is 0.7; 3) the 
type I error rate is 0.05; then 28 patients would be needed to test the hypothesis. 
For possible dropouts and later refusal to participate in the study, inclusion of 
40 patients was aimed. However, as IAP as well as other continuous variables 
were non-normally distributed, comparisons between groups were done using 
the Wilcoxon-Mann-Whitney test. As the worst that the Wilcoxon-Mann-
Whitney test could ever perform against the T-test is 0.864 in terms of asymp-
totic significance, 1/0.864 more patients, i.e. 33, would be needed certainly to 
achieve the same power (Hollander et al., 2014). Therefore, our sample size of 
37 patients was sufficient to test the primary hypothesis (i.e., a 3 mmHg change 






4.4.1.2. iSOFA study (IV)  
Sample size calculation for part A of the iSOFA study was based on studies 
(Reintam et al., 2008a; Reintam Blaser et al., 2013) demonstrating a ROC curve 
of the SOFA score in prediction of 28 day mortality of 0.75 (SD 0.25). A 5% 
absolute increase in the predictive ability of the SOFA score was aimed with the 
addition of a GI dysfunction score. A 28-day mortality of 20% was assumed in 
the study population. Accepting a type I error of 5% and a power of 90%, 450 
patients would be needed. To allow for a dropout rate of 10%, at least 500 
patients were aimed to be included. 
The calculation of the number of patients necessary in part B of the iSOFA 
study was based on I-FABP measurements in critically ill patients with sepsis 
(Derikx et al., 2007). With a type I error of 5%, a power of 90% and assuming 
that the probability of a randomly selected non-survivor having a higher out-
come value than a randomly selected survivor is 0.65, the number of patients 
needed to detect a difference in distribution using a Wilcoxon-Mann-Whitney 
test is 159. To allow for a 20% dropout and loss to follow-up, at least 199 




5.1. Enteral feeding protocol study (I) 
In total, 665 and 683 patients were admitted to the ICU before and after 
implementation of the feeding protocol, respectively. 231 patients admitted 
before and 249 admitted after implementing the enteral feeding protocol ful-
filled the inclusion criteria and were studied. There were no differences in 
patient age, sex, BMI, proportion of nonsurgical vs surgical admission types nor 
illness severity scores. Mechanical ventilation was slightly more frequent in the 
Before group (93.1% vs 86.7%, P=0.021). Overall, 53.3% of patients were ad-
mitted after surgery, including 29.4% after abdominal surgery. While ICU 
length of stay, duration of mechanical ventilation and incidence of hospital-
acquired infections were similar, long-term mortality rate was higher among 
patients in the Before group (90-day mortality 37.2% vs 28.5%, P=0.026; 120-
day mortality 38.5% vs 30.1%, P=0.033).  
After implementing the feeding protocol, EN was less frequently prescribed 
on day 1, but more frequently from day 3 onwards (Figure 3). Enteral caloric 





EN – enteral nutrition.  








Before After P-value 
Day 1 0 (0–100) 0 (0–0) 0.016 
Day 2 0 (0–480) 100 (0–480) 0.409 
Day 3 160 (0–700) 370 (0–767) 0.031 
Day 4 340 (0–800) 500 (10–960) 0.003 
Day 5 400 (0–1000) 580 (176–1100) 0.142 
Day 6 500 (53–1000) 695 (240–1138) 0.003 
Day 7 500 (108–1000) 720 (200–1155) 0.018 
 
Data presented as median (IQR), kcal. 
Figure 4. Daily enteral caloric intake. 
 
 
Median cumulative caloric intake during one week from enteral nutrition in-
creased after implementation of the feeding protocol: Before 2300 (IQR 380–
5030) kcal vs After 3210 (IQR 1280–5215) kcal (P=0.049). Simultaneously the 
provision of parenteral calories decreased: Before median 3977 (IQR 1775–
6646) kcal vs After median 2600 (IQR 825–4287) kcal (P<0.001). Accordingly, 
the overall median number of calories provided to patients during the first week 
was lower in the After group (7030 (IQR 5667–8970) kcal vs 6000 (4715–
7498) kcal, P<0.001) than in the Before group.  
The incidence of overfeeding in all analysed days decreased (Before 8.4%, 
After 4.5%, P<0.001), while underfeeding was more frequent (Before 59.4%, 
After 76.9%, P<0.001), largely related to less frequent use of PN. The caloric 
need was calculated for each patient using a weight-based equation and was the 
same on all study days, although was not targeted during the first days.  
Admission day risk factors for not receiving at least 80% of daily caloric 
needs via the enteral route by day 4 were identified as belonging to the Before 
group (OR 4.02, 95% CI 1.55–10.40), admission after abdominal surgery (OR 
3.97, 95% CI 1.26–12.46), a higher number of gastrointestinal symptoms (OR 
6.01, 95% CI 2.55–14.14) and presence of IAH (OR 4.20, 95% CI 1.32–13.34).  
No differences in the daily occurrences of vomiting, radiologically con-
firmed bowel distension, GI bleeding nor large GRV (>500 mL/d) were 
detected. Diarrhoea and IAH were more frequent in the After group on only one 
study day (day 4, diarrhoea: 7.6% vs 2.8%, P=0.022; day 5, IAH: 29.5% vs 
20.5%, P=0.043). The prescription of metoclopramide was similar between 
groups, with less frequent prescription in the After group on day 2 (3.6% vs 
9.1%, P=0.011).  
 
 
5.2. Gastrointestinal failure study (II) 
Out of the 3959 patients included in the study, 81.7% were mechanically 
ventilated on admission, sepsis (any severity) was seen in 30.7%, 45.8% were 
of surgical profile and 16.8% admitted after gastrointestinal surgery. 29% of 
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patients received enteral feeding on admission day. ICU length of stay was 
median 4 (IQR 2–10) days, ICU mortality 19.6% and 90-day mortality 33.9%. 
GIF, defined as concomitant occurrence of 3 or more GI symptoms, deve-
loped in 412 (10.4%) patients at some time during their stay in ICU, being 
present already on admission in 181 (4.5%). Thereafter, nearly 80% of cases of 
GIF occurred during the first week of ICU. Patients that developed GIF were 
older, more severely ill on admission to ICU and more often admitted after 
surgery, including GI surgery. A significantly smaller proportion of patients 
with GIF received EN on admission day compared to others (30.7% vs 14.5%, 
P<0.001). ICU length of stay (median 4 (IQR 2‒8) vs 11 (5‒25) days), duration 
of mechanical ventilation (median 2 (1‒6) vs 9 (3‒21) days) and mortality at 
ICU discharge (17.8% vs 34.9%, P<0.001), 30 days (26.5% vs 39.6%, P<0.001) 
and 90 days (32.1% vs 49.6%, P<0.001) were higher in patients with GIF. A 
Kaplan-Meier curve (Figure 5) illustrates the mortality difference in patients 
with vs without GIF. In multivariate regression analysis, a higher number of GI 
symptoms on admission day independently predicted 90-day mortality along-
side SOFA sub-scores for other organ failures (Table 6).  
 
 
GIF – gastrointestinal failure; ICU – intensive care unit. 




Table 6. SOFA sub-scores and number of GI symptoms. 
Multiple regression analysis for 90-day mortality 
Admission day variables OR Lower CI 95% Upper CI 95% P-value 
SOFA respiratory 1.094 1.015 1.179 0.019 
SOFA haematologic 1.189 1.101 1.283 < 0.001 
SOFA hepatic 1.164 1.063 1.274 0.001 
SOFA cardiovascular 1.453 1.368 1.543 < 0.001 
SOFA neurological 1.442 1.375 1.513 < 0.001 
SOFA renal 1.345 1.279 1.415 < 0.001 
Number of GI symptoms 1.331 1.214 1.460 < 0.001 
OR – odds ratio; CI – confidence interval; SOFA – Sequential Organ Failure 
Assessment; GI – gastrointestinal. 
 
 
GIF was caused by a primary gastrointestinal pathology in 253 (61.3%), while 
secondary GIF was present in 160 (38.7%). Patients with primary GIF com-
pared to those with secondary GIF were more frequently female, had lower ill-
ness severity scores (APACHE II median 14 (IQR 10–19) vs 20 (14–26) points, 
P<0.001; SOFA median 7 (5–10) vs 9.5 (7–12) points, P<0.001) and lower 
lactate level on admission to ICU, less fluids administered in the first 24h, but 
more frequent sepsis on admission. Enteral nutrition was more frequently used 
on admission day in patients with secondary GIF (25% vs 7.9%, P<0.001). 
During the first five days and on day 10, patients with primary GIF experienced 
more GI symptoms compared to those with secondary GIF. Mortality at ICU 
discharge and at 30 and 90 days was slightly higher in patients with secondary 
GIF, but these differences were not statistically significant. 
Intra-abdominal hypertension was detected in 245 (59.3%) patients with GIF 
and 635 (17.9%) patients without GIF (P<0.001). IAH occurred in 166 (65.6%) 
patients with primary and 79 (49.4%) patients with secondary GIF (P=0.001). 
IAP was not measured in 9.1% of patients with primary and 21.3% of patients 
with secondary GIF. 
 
 
5.3. Intra-abdominal pressure and sedation study (III) 
37 patients were included in the study. 28 (75.7%) were male, median age was 
59 (range 29–81) years, BMI 33.0 (29.9–36.7) kg/m2, 24 (64.9%) were admitted 
to ICU with a nonsurgical diagnosis and the most common pathologies on ad-
mission were pancreatitis in 11 (29.7%), pulmonary pathologies in 8 (21.6%) 
and neurological pathologies in 5 (13.5%) of patients. The severity of IAH at 
baseline was: grade I (12–15 mmHg) 2 patients (64.9%), grade II (16–20 
mmHg) 11 patients (29.7%) and grade III (21–25 mmHg) 2 patients (5.4%). 
















































































































































































































































































































































































































































































































































































































































































































Protocol-based deepening of sedation was effective in most patients as detected 
by RASS. Other sedative drugs, used at baseline, were continued throughout the 
intervention in unchanged doses. Median doses used were: midazolam (N=7) 3 
(3‒4) mg/h; fentanyl (N=22) 50 (50‒100) µg/h; dexmedetomidine (N=4) 88 
(68‒108) µg/h; clonidine (N=1) 60 µg/h. Median intra-abdominal pressure was 
15 (IQR 13–16) mmHg at baseline and decreased by 1 mmHg at all time points 
(difference significant: after bolus and at 60 minutes of infusion). Any decrease 
in IAP compared to baseline was seen in 91.9% patients, whereas a decrease of 
≥3 mmHg was observed in 9 (24.3%) patients.  
MAP and APP was reduced at all time points compared to baseline, with 
lowest values observed after the bolus dose of propofol. Vasoactive therapy 
with noradrenaline was used in 22 (59.5%) patients at baseline; in 10 of them 
the dose of noradrenaline was increased (statistically non-significant) and in 6 
additional patients a noradrenaline infusion was started during the intervention 
as guided by the haemodynamic management algorithm.  
Respiratory rate decreased during the intervention, but cessation of sponta-
neous respiratory efforts occurred in a minority of patients. There were no signi-
ficant changes in tidal volume nor plateau pressures during the intervention.  
 
In regression analyses to detect baseline characteristics associated with IAP 
decrease by 30 minutes of propofol infusion, a greater cumulative positive fluid 
balance (regression coefficient –0.156 (95% CI -0.301 to -0.012, P=0.035) and 
a lower SOFA score (regression coefficient 0.187 (95% CI 0.027–0.348, 
P=0.024) were independently associated with greater treatment effect.  
 
5.4. iSOFA study (IV) 
A total of 540 patients were included across 11 study sites: Bern (N=50), Tal-
linn (N=50), Tartu (N=61), Vienna (N=49), Stockholm (N=50), Brussels (N= 
57), Buenos Aires (N=25), Kiel (N=56), Luzern (N=60), Maastricht (N=57), 
Paris (N=25). Admission and outcome data are presented in Table 8. 
 
 
Table 8. Admission characteristics and outcome data. 
Male gender 328 (60.7) 
Age, years (range) 65 (18‒94) 
BMI, kg/m2 26 (23;29) 
APACHE II, points 17 (11;24) 
Simplified Acute Physiology Score II, points 38 (26;53) 
SOFA, points 6 (3;9) 
Profile  
     Nonsurgical 223 (41.3) 
     Elective surgical 193 (35.7) 
     Emergency surgical 124 (23.0) 
 
50 
Main reason for ICU  
     Postoperative care with mechanical ventilation 165 (30.6) 
     Postoperative care without mechanical ventilation 93 (17.2) 
     Respiratory failure 69 (12.8) 
     Neurological deterioration 61 (11.3) 
     Shock 59 (10.9) 
     Cardiac failure 38 (7.0) 
     Metabolic disorder 10 (1.9) 
     Other organ failures 15 (2.8) 
     Multiple organ failure 9 (1.7) 
     Renal failure 6 (1.1) 
     Other reason 30 (5.6) 
Abdominal surgery 104 (19.3) 
     of which GI surgery 62 (11.5) 
Invasive mechanical ventilation  305 (56.5) 
Vasopressor/inotrope 311 (57.6) 
OUTCOME  
ICU length of stay  3 (1‒6) 
Duration of mechanical ventilation  1 (0‒4) 
28-day mortality (N=539) 79 (14.6) 
90-day mortality (N=522) 102 (18.9) 
Data are presented as N (%) or median (IQR) if not stated differently. BMI ‒ body mass 
index; APACHE - Acute Physiology and Chronic Health Evaluation; SOFA – Sequential 
Organ Failure Assessment; ICU – intensive care unit;  GI – gastrointestinal.  
 
 
The descriptive AGI grading was independently associated with mortality to-
gether with both the SOFA score and its sub-scores separately (data not shown).  
Thereafter, a new score was developed based on the rationale of the AGI 
grading and using single GI symptoms and conditions. As citrulline and I-FABP 
were not clearly associated with mortality in univariate and multivariate ana-
lyses, they were initially omitted in the score development process. Addition of 
biomarkers to the final version of the new score – GIDS – was tested with no 
significant improvement in mortality prediction. The newly developed GIDS is 
shown in Table 9 and Kaplan-Meier curves with the descriptive AGI grading 













































































































































































































































































































































































































































































































































































Categories from 0 to 4 differed significantly (P<0.0001, Log rank test) in both the 
original AGI grading and the New AGI score. 
No. of patients in categories: AGI 0 – 217, AGI 1 – 183, AGI 2 – 81, AGI 3 – 25, AGI  
4 – 16; GIDS 0 – 227, GIDS 1 – 119, GIDS 2 – 141, GIDS 3 – 13, GIDS 4 – 16. 
AGI – Acute Gastrointestinal Injury; GID – Gastrointestinal Dysfunction; ICU – 
intensive care unit. 
 
Figure 6. Kaplan-Meier survival curves with cumulative 90 days survival based on 





The performance of the GIDS together with SOFA score and its sub-scores in 
mortality prediction is shown in Table 10.  
 
 
Table 10. Gastrointestinal Dysfunction Score (GIDS) in prediction of mortality alone 
and together with SOFA score as time-dependent variables in centre-stratified Cox 
regression analysis. 
Unadjusted univariate analyses 
 Mortality during 28 days Mortality during 90 days 
Covariate HR (95% CI) P-value HR (95% CI) P-value 
GIDS 2.15 (1.76‒2.63) 6.39 ∙ 10  2.09 (1.72‒2.53) 3.40 ∙ 10  
Multivariate analyses 
 Mortality during 28 days Mortality during 90 days 
Covariates HR (95% CI) P-value HR (95% CI) P-value 
Model 1: SOFA total + GIDS 
SOFA total 1.23 (1.16‒1.30) 9.53 ∙ 10  1.23 (1.16‒1.29) 8.70 ∙ 10  
GIDS 1.40 (1.07‒1.84) 0.014 1.40 (1.02‒1.79) 0.005 
Model 2: SOFA subscores + GIDS 
SOFA cardio-
vascular 
1.15 (0.95‒1.41) 0.136 1.13 (0.95‒1.34) 0.162 
SOFA 
respiratory 
1.20 (0.92‒1.56) 0.167 1.25 (1.01‒1.54) 0.036 
SOFA haema-
tological 
0.88 (0.65‒1.20) 0.422 0.89 (0.67‒1.18) 0.425 
SOFA renal 1.48 (1.22‒1.80) 5.54 ∙ 10  1.37 (1.14‒1.65) 0.0005 
SOFA hepatic 1.00 (0.72‒1.40) 0.994 1.05 (0.77‒1.43) 0.758 
SOFA neuro-
logical 
1.59 (1.30‒1.94) 4.96 ∙ 10  1.58 (1.31‒1.89) 6.90 ∙ 10  
GIDS 1.48 (1.13‒1.92) 0.003 1.47 (1.15‒1.87) 0.001 
HR – hazard ratio; CI – confidence interval; GIDS – Gastrointestinal Dysfunction 





5.5. Enteral nutrition and biomarkers study (V) 
224 patients with 693 measurements of citrulline and 695 measurements of I-
FABP were included in this study. Median age was 67 (range 19–94) years and 
137 (61.2%) patients were male. Admission categories were elective surgical in 
122 (54.5%), nonsurgical in 61 (27.2%) and emergency surgical in 41 (18.3%) 
patients. 42 (18.8%) patients were admitted after abdominal and 34 (18.8%) 
after gastrointestinal surgery. Admission day median APACHE II score was 18 
(IQR 11–23), median Simplified Acute Physiology Score II score 39 (IQR 26–
53) and median SOFA score 6 (IQR 4–9) points.  
Median ICU length of stay was 2 (IQR 1–4) days, with 35 (15.6%) patients 
being long-stayers (≥7 days). Mortality was 7.1% at ICU discharge, 10.3% at 28 
days and 14.7% at 90 days. 
Median level of citrulline on admission was 24.5 (IQR 18.1–31.7; range 6.2–
134.2) µmol/L and that of I-FABP 2763 (IQR 1326–4805; range 73–228328) 
pg/mL. The dynamics of the biomarkers are shown in Figure 7.  
184 (82.1%) patients received enteral or oral nutrition during their ICU stay. 
Those not receiving any nutrition were mostly short-stayers with a median ICU 
stay of 1 (IQR 1–2) days. Early enteral or oral nutrition (EEN/ON; started 
within 2 days of ICU admission) was provided to 164 (73.2%) patients, 
however only 41 (18.3%) patients received EEN. Out of 164 patients receiving 
EEN/ON, 60 (36.6%) were in the ICU by day 4 and 39 of them (65%) were 
successfully fed by day 4 (defined as receiving 80% of the caloric target via EN 
or oral diet in any amount).  
Different dynamics of citrulline over time were seen between patients that 














































































































































































































































































































































































Patients receiving EEN/ON were compared based on increasing (69%) or de-
creasing (31%) citrulline values from day 2 to day 4. The proportion of patients 
receiving EEN/ON on day 3 was higher among patients with increasing citrul-
line (100% vs 79%, P=0.026), but similar and >90% on days 2 and 4. Caloric 
intake on days 3 and 4 was similar between the groups. In patients with in-
creasing citrulline values, the median AGI grade was lower on day 4 (0 (0–1) vs 
1 (1–2), P=0.008) and prokinetics were used less frequently (13 vs 57%, 
P=0.004). Between patients receiving EEN/ON with increasing vs decreasing 
citrulline, the prevalence of GI symptoms was similar, as well as the SOFA 
score, ICU length of stay and 28-day mortality. 
Successful EEN/ON (>80% of caloric needs achieved via EN or any amount 
of oral nutrition) was not associated with different dynamics nor average values 
of citrulline nor I-FABP over the first week, compared to patients failing to 
achieve that threshold.  
Patients who left ICU before day 7 and therefore had an incomplete dataset 
(N=189), had higher citrulline values compared to long-stayers on day 1 (25.3 
(19.3‒32.8) vs 19.7 (15.3‒26.0) µmol/L, P=0.011) and day 3 (18.1 (14.8-24.2) 
vs 15.7 (11.9-19.8), P=0.030). Citrulline values on other days and I-FABP 
values did not differ between these groups.  
On admission to ICU, patients with renal failure (defined as SOFA renal 
subscore ≥2) had similar citrulline values as those without renal failure. There 
was an overall weak positive correlation between creatinine and citrulline va-
lues, r (650) = 0.228, P < 0.001, and a very weak negative correlation between 
24-hour urine output and citrulline values, r (650) = -0,132, P = 0.001.  
Admission day I-FABP values did not differ in patients with renal failure 






6.1. Enteral feeding protocol study (I)  
The first study of this dissertation describes the nutritional practices before and 
after implementing an enteral feeding protocol in the 1st ICU of the Tartu Uni-
versity Hospital. A major finding is that among ICU long-stayers, EN can be 
enhanced in a safe manner using a feeding protocol.  
After implementing the feeding protocol, the median caloric intake from EN 
during the first week of ICU increased by 40% and the proportion of patients 
receiving EN was higher on all days from day 3. EN being used more but slight-
ly later may be explained by knowledge on the concepts of autophagy and non-
inferiority of early underfeeding becoming incorporated into clinical practice at 
the time of conduction of the study. This finding is likely also related to 
adherence to the list of conditions where EN should be delayed, specified in the 
feeding protocol, as the high admission SOFA score and prevalence of vaso-
pressor and mechanical ventilation use illustrate the high illness severity of the 
patients included.  
In general, our finding of improvement in the provision of EN is in accor-
dance with other studies evaluating the effect of EN protocols. Most of the evi-
dence originates from similar before-and-after studies while some randomised 
controlled trials have also been performed. A relatively recent review of such 
studies summarises that, as a whole, protocolised EN therapy leads to optimised 
nutrition, with a variety of different success measures used across studies, e.g. 
percentage of achieved nutritional goals, time until initiation and duration of 
nutrition therapy (Ventura & Waitzberg, 2015).  
A simultaneous decrease in the use of PN took place in the After period. The 
median amount of parenterally provided calories decreased by more than was 
the increase in enterally given calories and therefore, somewhat unexpectedly, 
the overall cumulative caloric intake during the first week of ICU decreased 
from a median of 7000 to 6000 kcal per week. Decisions regarding PN were at 
the discretion of the intensive care physicians both before and after imple-
menting the feeding protocol. Results from the EPaNIC study (Casaer et al., 
2011), demonstrating harm from early initiation of PN causing full or possibly 
even overfeeding, may have influenced decisions regarding PN predominantly 
in the After period of the study. A reduction in the use of PN could therefore 
have been partly unrelated to the use of the feeding protocol. In addition, the 
more frequent use of and higher caloric provision via EN may have influenced 
the clinicians’ decision to withhold PN altogether in some patients. The use of 
(full) PN may have been reserved to those in whom EN was not used, less 
frequent in the After period. Altogether, likely a combination of these inter-
actions led to an important caloric deficit in the first week of long-staying ICU 
patients. Although the energy utilization of critically ill patients varies con-
siderably, for an average caloric need of 2000 kcal per day and 14 000 kcal per 
week, a median deficit of around 8000 kcal occurred. Even though according to 
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current knowledge, full needs should not be attempted to achieve with artificial 
nutrition in the catabolic phase of critical illness, extensive deficits should still 
be avoided and cumulative caloric debts of already >4000 kcal have been 
shown to be associated to an increased risk of complications (Dvir et al., 2006). 
Bearing in mind that 30% of our patients were admitted after abdominal surgery 
and subsequently stayed in the ICU for ≥7 days, constituting a nutritionally 
highly challenging population, a comprehensive strategy also involving the in-
dications and timing of supplemental or full parenteral nutrition would be most 
helpful in preventing iatrogenic malnutrition. 
Overfeeding was infrequent both before and after implementing the feeding 
protocol. Seemingly trivial but important in the context of overfeeding, are 
sources of energy outside EN and PN, mainly received in the form of glucose-
based maintenance solutions, lipid emulsion of the sedative drug propofol and 
by metabolizing the anticoagulant citrate used in renal replacement therapy. 
These non-nutritional calories may account for one third of all given calories in 
the first days during the start-up of nutrition, and stabilise later at a mean of 6% 
for glucose and/or propofol and at 18% for citrate anticoagulation (Bousie et al., 
2016). In study I, calories from glucose solutions, but not those from propofol 
and citrate anticoagulation was included in the calculation of parenterally admi-
nistered calories. It is not clear whether and to which extent the amount of non-
nutritional calories influenced the decisions about the nutrition prescribed in the 
Before and After periods, however the real incidence of overfeeding was pro-
bably somewhat greater than demonstrated. Vice versa, the true incidence of 
underfeeding may have been lower in our patient population.  
In some studies, a positive effect of protocolised nutrition has been shown on 
the incidence of infectious complications and outcomes (Taylor et al., 1999; 
Martin et al., 2004; Heyland et al., 2013). In our study, the incidence of 
hospital-acquired infections was similar between the study periods. Lower long-
term mortality seen in our study likely reflects changes in other aspects of both 
ICU and post-ICU management, but some effect of improved EN cannot also be 
excluded.  
Gastrointestinal symptoms are frequent among critically ill patients and as-
sociated with complications. Indeed, in study I we demonstrated that develop-
ment of GI symptoms was independently and out of all factors, most strongly 
associated to insufficient EN. Therefore, an important finding of study I is that 
protocolised EN resulting in increased use and dose did not cause harm – daily 
incidences of GI symptoms and IAH were similar both before and after imple-
menting the feeding protocol, with a few statistically significant differences 
likely explained by chance. In other studies looking at the rate of complications 
with protocols where EN is increased incrementally, improvement in EN has 
similarly been well tolerated, with no increases in the incidences of high GRVs, 
vomiting or ventilator-associated pneumonia (Arabi et al., 2004; Reignier et al., 
2010). A common, important feature of feeding protocols, also in our study, is 
guidance on how to address intolerance, including reducing the dose of EN. 
Accordingly, more severe complications e.g., tracheal aspiration of gastric 
60 
contents, or mesenteric ischaemia, may be avoided. Another possible explana-
tion for no observed increase in the incidence of GI symptoms or IAH is that the 
improvement in the provision of EN was modest (a median increase of about 
200 kcal or mL per day compared to the Before period), not sufficient to cause 
signs of intolerance on top of the already low baseline provision of EN.  
A recurring theme in the literature is suboptimal adherence to nutrition 
protocols (Ventura & Waitzberg, 2015). In study I, the compliance of physi-
cians and nurses with the feeding protocol was not specifically assessed and 
therefore is unknown. Low adherence to a protocol, in general, may be a cause 
for falsely negative or modest results. 
 
 
6.2. Gastrointestinal failure study (II)  
Gastrointestinal symptoms  
In study II, six GI symptoms were used to define gastrointestinal dysfunction, 
with simultaneous presence of at least three GI symptoms in one day consti-
tuting GI failure. GIF occurred in 10% of patients during their ICU stay. 
Development of GIF was associated with substantially worse treatment 
outcomes, including a threefold increase in ICU length of stay and a twofold 
increase in mortality rate. When the number of GI symptoms experienced on 
admission day was added to the subscores of the SOFA score, all were inde-
pendently predictive of 90-day mortality, while addition of GI symptoms 
slightly improved the predictive capability of the SOFA score.  
Findings of this study once more illustrate the importance of gastrointestinal 
problems in critically ill patients and suggest that GI dysfunction itself can be a 
cause of poor outcome and not just an epiphenomenon related to a general cri-
tical condition. Compared to the original study defining GIF by the presence of 
≥3 GI symptoms, GIF was more frequent in our patient population (10.4% vs 
6.4%) (Reintam Blaser et al., 2013). In that study, mechanically ventilated ICU 
patients were monitored during the first 7 days, while we observed the whole 
ICU stay. At the same time, illness severity and ICU mortality were higher in 
their study, therefore, the difference in the incidence of GIF could not be ex-
plained by GI problems occurring alongside other organ failures. The earlier 
study also included more surgical, including abdominal surgery patients, in 
whom more GI symptoms and thus, a higher incidence of GIF, could be ex-
pected. This suggests that many cases of GIF develop later in the course of criti-
cal illness, after the initial pathology that required ICU admission has subsided. 
Indeed, in our patients, 20% of cases of GIF occurred beyond the first week.  
Nearly two thirds of patients with GIF had a primary disease in the abdomi-
nopelvic region, being admitted mostly after surgery, in half of patients per-
formed on the GI tract. These patients experienced a higher number of GI 
symptoms during the first week of ICU. Contrarily, patients with secondary GIF 
mostly had a nonsurgical pathology on admission to ICU and a wider list of 
underlying pathologies. Cases of GIF with a primary cause occurred signi-
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ficantly earlier than those with a secondary aetiology. Sepsis, known to be as-
sociated with poor outcomes in ICU patients, was more frequent among patients 
with primary compared to secondary GIF (53.6 vs 42.5%, P = 0.034). Outcomes 
including length of mechanical ventilation and ICU stay as well as mortality, 
however, were consistently slightly worse in patients with secondary GIF, 
although not reaching statistical significance. It can be argued that outcomes are 
better if an abdominal pathology, including sepsis with an abdominal origin, can 
be treated promptly and efficiently. In patients with critical illness involving 
multiple organ systems, GIF occurring secondarily and later during their illness 
may not be as amenable to treatment.  
Although development of GI symptoms was firmly associated with poor out-
come, the subjectivity and probably different weight of single symptoms makes 
a definition based only on symptoms imprecise. Furthermore, considering GI 
dysfunction as a continuum rather than a yes/no phenomenon (failure) is pro-
bably more meaningful. Addition of more objective variables, including IAP 
and biomarker values, and considering the weight of each symptom together 




To detect elevation of IAP, it must be measured. Currently there is no consensus 
in which patients should IAP measurements be instituted. It would be desirable 
not to miss many cases of IAH while avoiding unnecessary measurements in 
patients in whom IAH is unlikely to develop. There are some patient groups in 
whom IAH is less frequent and omitting IAP monitoring has been suggested. In 
a single centre observational study with an ICU stay ≥24 hours, these included 
mechanically ventilated patients with positive end-expiratory pressure (PEEP) 
<10 cmH2O, pO2/FiO2 >300 mmHg, BMI <30 and none of the following: 
pancreatitis, liver failure with ascites, GI bleeding, laparotomy and use of vaso-
pressors or inotropes (Reintam Blaser et al., 2011b). Conversely, independent 
risk factors for development of IAH at any time during ICU stay were recently 
identified as BMI ≥27 kg/m2, APACHE II score greater than 18, abdominal 
distension, absence of bowel sounds and PEEP >7 cmH2O, and additionally 
positive fluid balance for development of IAH beyond day 1 (Reintam Blaser et 
al., 2019). IAH is twice as prevalent in mechanically ventilated compared to 
spontaneously breathing patients (Reintam Blaser et al., 2019). However, in-
creasing the proportion of patients with IAP measurements does not necessarily 
translate into more cases of IAH detected (Reintam Blaser et al., 2014a). The 
creation of a tool to predict the development of IAH in an individual patient 
would be most helpful and is underway.  
In study II, IAP was measured in 46% of patients during their ICU stay. 
Importantly, the 3959 patients were admitted during a 12-year period, entailing 
several practice changes. In patients with GIF (3 simultaneous GI symptoms 
during1 day), IAP was measured in nearly 90%, while those with GIF due to an 
extra-abdominal condition received IAP measurements less frequently (79%). 
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On the other hand, IAH was frequent among patients with GIF, occurring in 
60% of them. These results suggest that IAP measurements are more easily 




6.3. Intra-abdominal pressure and sedation study (III) 
In study III, the effect of protocolised deepening of sedation with propofol on 
IAP and haemodynamic and respiratory parameters was assessed in mecha-
nically ventilated patients with IAH. Deepening of sedation according to RASS 
was achieved in most patients. The patient population consisted of mostly male 
patients with a nonsurgical illness. There was a high prevalence of obesity, IAH 
was mostly mild (grade I) and the frequencies of primary and secondary IAH 
were balanced.  
IAP decreased in most patients during the intervention, with a median de-
crease of 1 mmHg from baseline. This change in IAP is comparable to the intra-
observer variability – 0.57 mmHg – of the pressure measurement device used 
(Kimball et al., 2007). Compared to other medical/minimally invasive manage-
ment options of IAH, used as first line interventions to avoid sustained and 
worsening IAH, this effect across the overall study population is probably clini-
cally insignificant. For example, a decrease in IAP of 4 mmHg has been shown 
with the use of neuromuscular blockade (De Laet et al., 2007) and changing the 
body position from head-of-bed elevation to supine (Cheatham et al., 2009). In 
some specific instances, percutaneous drainage of large volume ascites may be 
very effective in reducing IAP and avoiding a surgical approach to resolve ACS 
(Umgelter et al., 2008; Cheatham & Safcsak, 2011). In patients with abdominal 
burn injuries suffering from ACS, the use of escharotomy as a method for ab-
dominal decompression can significantly reduce IAP and improve haemodyna-
mics and ventilation without the need to create an open abdomen (Oda et al., 
2005). Indeed, the nature and course of the clinical condition together with the 
effect of IAP on organ function(s) should also be taken into account beside the 
measured IAP value, when deciding whether and with which method should 
IAH be treated (De Laet et al., 2020). The same principle likely holds true when 
deciding whether to apply deep sedation in a patient with IAH. In study III we 
saw that approximately one quarter of patients demonstrated a decrease in IAP 
of ≥3 mmHg with deep sedation. Therefore, it would be helpful if we could 
predict in which patients the intervention will be helpful and in which patients it 
could be rather harmful and should be avoided in the absence of expected effect 
and considering side effects. According to regression analysis, patients with a 
greater previous fluid balance and less severe illness seemed to experience a 
greater treatment effect with deepening of sedation. The impact of these base-
line characteristics was very low and does not help to guide in which patients 
should sedation be deepened. Therefore, we believe that in the absence of good 
predictors, a trial of deep sedation is justified if IAH is considered as needing 
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treatment, bearing in mind possible side effects of prolonged deep sedation, 
including inhibition of GI motility. If IAP does not change or there is an 
extensive haemodynamic effect, deep sedation could then be discontinued.  
While the effect on IAP was in general small, a noticeable impact on haemo-
dynamics was observed. Prolonged hypotension was avoided with prompt use 
of a vasopressor drug to counteract the propofol-induced vasodilation. In 40% 
of patients, noradrenaline was either started during the intervention or its dose 
increased, while in only 1 patient the dose of propofol needed to be decreased 
due to an excessive increase in the dose of vasopressor, as specified by the stu-
dy protocol. Haemodynamic management in the study was guided by MAP 
goals. Similar to cerebral perfusion pressure (mean arterial pressure minus intra-
cranial pressure), the effective perfusion pressure in the abdomen may be more 
important in determining the perfusion of abdominal organs. Whether it is a 
better treatment endpoint than MAP or IAP in patients with IAH, is currently 
not known, although some authors suggest to consider APP >50–60 mmHg as a 
treatment end-point (Malbrain & De Waele, 2013) with few data supporting this 
suggestion (Cheatham et al., 2000; Al-Dorzi et al., 2012). In our study, if APP 
instead of MAP would have been used to guide fluid and/or vasopressor therapy 
in patients with IAH, even greater vasopressor doses would have been needed to 
achieve APP >60 mmHg. 
No improvements in respiratory volumes nor decreases in respiratory pres-
sure were seen with the intervention, possibly related to the low overall effect 
on IAP. PEEP was 10 (8–12) cmH2O, but it was unchanged during the inter-
vention and the effect on IAP at PEEP values <12 cmH2O is likely marginal 
(De Keulenaer et al., 2009). Respiratory activity ceased completely in only one 
quarter of patients. Theoretically, abdominal compliance could be improved by 
reducing the tone in the muscles of the abdominal wall, including the dia-
phragm, by complete cessation of spontaneous respiration. However, in patients 
in whom spontaneous breathing stopped with deep sedation, the decrease in IAP 
was similar compared to others.  
Obesity, a known risk factor for IAH, was prevalent in our patient popu-
lation. As pre-ICU IAP values are not known, it is difficult to distinguish 
whether an elevated IAP value in an obese patient is acute or chronic and 
whether it can or should be lowered. In this study, IAP changed similarly in 
obese and normal-weight patients in response to deepening of sedation.  
An important limitation of this study is that the sedation end-point was 
defined by a drug dose and not a sedation or respiratory parameter. Some pa-
tients did not achieve a very deep sedation or complete cessation of spontaneous 
breathing, possibly diluting the results. Further, with the exclusion of awake and 
agitated patients we may have omitted those who could benefit the most from 
deeper sedation in terms of IAP reduction. A long study conduction period and 
the fact that not all consecutive eligible patients were recruited brings along a 




6.4. iSOFA study (IV) 
In the iSOFA study, 540 consecutively admitted intensive care patients from 11 
centres in 9 countries were observed during their first week of ICU, with daily 
data collection including predefined abdominal and GI symptoms (Reintam 
Blaser et al., 2012), AGI grading and biomarkers citrulline and I-FABP. As the 
original AGI grading performed well in mortality prediction, a new score, 
named the GIDS, was created based on the logic of AGI grading. Inclusion of 
biomarkers did not improve the score. When added to the SOFA score, GIDS 
was independently associated with 28- and 90-day mortality and slightly im-
proved the predictive power of the SOFA score. 
Compared to previous attempts at creating a score to quantify gastrointes-
tinal dysfunction in critically ill patients, all consecutive patients were included 
and prospective data collection used. A complex, stepwise statistical approach 
allowed to take into account the individual contribution of different symptoms 
and conditions towards mortality prediction. 
The original AGI grading (Reintam Blaser et al., 2012) has been shown to be 
related to mortality in several studies in the recent years (Hu et al., 2017; Zhang 
et al., 2018; Loudet et al., 2020; Ding et al., 2020). Likewise, in this study it 
performed well in prediction of mortality both alone and together with the 
SOFA score and its subscores. Furthermore, the AGI grading was the best-func-
tioning component of these models. Instead of specific GI symptoms, AGI con-
siders the overall condition of the patient and includes a great deal of subjecti-
vity in determining whether the GI or other organ system(s) may drive a dete-
rioration of a patient’s condition. A higher AGI grade may be given in a patient 
with multiorgan dysfunction compared to a less severely ill patient with exactly 
the same GI symptoms. Therefore, assessment of other organ dysfunctions may 
contribute to determining an AGI grade, likely also explaining the best predic-
tive ability out of all organ dysfunction scores. Further, lack of clear definition 
of feeding intolerance within AGI adds another component of subjectivity. 
It could be argued that organ dysfunction can better be described by mea-
suring some specific function(s) of the organ system, rather than by its ability to 
predict outcome. Firstly, the intricacy of the GI system, critical illness and the 
intensive care environment precludes an easily applicable method to consider at 
the same time several different aspects of GI function, including its motor func-
tion, perfusion and absorption, as well as permeability and other non-digestive 
aspects. Secondly, the SOFA score, currently the most widely used in assessing 
organ dysfunction, but missing a GI component, has also been validated against 
mortality (Minne et al., 2009). Therefore, a mortality endpoint was chosen. Al-
ready more than two decades ago, authors of the SOFA score noted the impor-
tance of including the GI system in the score but deemed it too complex (Vin-
cent et al., 1996). The GIDS should undergo further validation to consider 
including it in a score assessing multiple organ dysfunction. 
The score is composed of 4 grades of severity, with 0 points corresponding 
to a normal functioning of the GI tract in an intensive care patient. The situation 
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where a patient was able to eat and experienced just one GI symptom or had 
grade I-II IAH was best categorised as 0 points. Included in this list of symp-
toms are also abdominal distension and GI paralysis. Even though these symp-
toms were associated with increased mortality in some of the multivariate 
analyses exploring associations of single symptoms with outcome, the perfor-
mance of the score worsened when considering these symptoms individually as 
being more “severe”. Thus, it seems that the concurrent presence of several 
symptoms is more informative than any single symptom. The score performed 
best, however, when abdominal distension and GI paralysis were also included 
in the list of more severe symptoms under GIDS=3.  
The ability of an intensive care patient to eat could be considered an impor-
tant feature of normal GI function. As such and also being beneficial to the 
performance of the score, it was incorporated in GIDS. However, including oral 
intake in the score may introduce the effect of other organ systems, as indepen-
dent eating also requires consciousness, sufficient respiratory function etc. 
Further, some patients unable to eat due to for example, a swallowing disorder, 
may be “falsely” classified from GIDS=0 to GIDS=1.  
IAH is not a measure of GI function per se, although associations with GI 
symptoms have been demonstrated as discussed before. Inclusion of IAP may 
increase the objectivity of the score and likely complements the assessment of 
GI symptoms. Similar to other less severe GI symptoms, occurrence of isolated 
grade I-II IAH does not suggest presence of GI dysfunction and anticipated 
poor outcomes, also supported by research in patients undergoing elective ab-
dominal hernia repair and transient IAH in the postoperative period (Petro et al., 
2015). 
We chose to define GIDS=4 as certain life-threating conditions arising from 
the GI tract – bleeding with haemorrhagic shock, mesenteric ischaemia and ab-
dominal compartment syndrome. With this approach, however, the influence 
from other organ systems likely remains. Defining GIDS=4 as a critical con-
dition is based on the logic of the AGI grading. It was evident from the 
discriminant analyses of single symptoms that no particular symptom or a 
number of symptoms could satisfactorily describe such a state. 
Although desirable as objective components, addition of citrulline or I-
FABP to the score did not improve its performance. Despite not being related to 
mortality, associations with enteral nutrition and possibly enterocyte function 
are not excluded and were indeed demonstrated in study V. As there exists no 
standard to measure the functioning of the GI tract in critically ill patients, 
choosing the most suitable outcome variable is difficult. Ideally, a clinical score 
would be able to both accurately identify organ dysfunction as well as predict 
outcome. 
Unfortunately, the biomarkers were measured in only a subset of the whole 
iSOFA study population due to financial constraints, possibly weakening their 
effect in the current analysis. 
GIDS, being developed on a prospective multicentre population of con-
secutively admitted ICU patients, deserves further validation studies to consider 
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using it for clinical and research purposes. Although some of the single symp-
toms remain subjective, for the time being the available components are the 
most practical.  
 
 
6.5. Enteral nutrition and biomarkers study (V) 
In study V, patients were prospectively observed during the first week of ICU to 
assess the dynamics of the biomarkers citrulline and I-FABP in response to 
EEN and its success. The patient population between studies I and V differs 
considerably. Study V included consecutive patients, including short-stayers ad-
mitted after major, mostly cardiac surgery, while abdominal surgery preceded 
ICU admission less often (29% vs 19%). Consequently, while illness severity 
according to APACHE II and SOFA scores was rather similar, mortality was 
lower in patients of study V. Nutrition was given according to local practices, 
with about 80% receiving enteral or oral nutrition at any time during their ICU 
stay. 50% of patients received early oral nutrition and 20% received EEN. A 
stepwise increase in enteral caloric intake was observed with a median of about 
1000 kcal per day provided after day 4 in those receiving EN.  
On the background of an overall decrease during the first week of ICU in the 
values of citrulline from normal to low-normal, a few interesting findings 
emerged related to the application of early enteral or oral nutrition. From day 3 
onwards, increasing citrulline levels were observed in patients who had received 
EEN/ON, unlike in those who did not. It seems that enteral or oral nutrition is 
associated with recovery of enterocytes, reflected by citrulline plasma concent-
ration. A recent study, part of the NUTRIREA-2 project, comparing the dyna-
mics of citrulline in patients receiving either enteral or parenteral nutrition sup-
ports this assumption, demonstrating a greater recovery of citrulline values 
during the first week in those who received EN vs those who were given 
exclusively PN (Piton et al., 2019). The direction of the association observed in 
our study and that by Piton et al, however, is not entirely clear. Whether nutri-
tion increases citrulline by providing glutamine, a precursor for its synthesis, or 
nutrition itself helps restore the enterocytes, or it is the recovery of enterocytes 
that makes giving EN possible, remains to be clarified. Citrulline levels failed to 
increase in about one third of patients receiving EEN/ON. These patients 
showed signs of feeding intolerance, demonstrated by interruption of nutrition 
in ~20%, higher AGI grades and more frequent use of prokinetics. Again, this 
finding of FI being related to non-recovery of citrulline values needs to be 
explained in further studies. In patients with early ON in any amount or EEN 
and receiving at least 80% of caloric needs by day 4, citrulline values increased 
and diverged visually from day 4 onwards from patients receiving <80%, how-
ever this trend was not statistically significant, likely affected by small patient 
numbers. 
In general, high values of I-FABP were observed on admission to ICU, with 
a rapid subsequent decrease into “normal” values, i.e., into the lower part of the 
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reference range of the laboratory kit used. Patients who received EEN/ON pre-
sented similar dynamics, but on average higher values during the first week, 
compared to their counterparts. A similar dynamic of I-FABP during the week 
was observed in patients with successful EEN/ON, but a trend towards higher 
average values was seen compared to those receiving <80% of caloric needs by 
day 4. These findings allow to hypothesise that enteral nutrition in the early 
phase of critical illness may be associated with enterocyte damage, caused by an 
imbalance in the delivery and demand of oxygen. In the study by Piton et al. 
comparing EN vs PN, EN was given early and in full amount to patients in 
shock (Piton et al., 2019). Three-to-four-fold greater values of I-FABP were 
observed in patients receiving EN vs PN during the one-week observation 
period with no cases of clinically obvious acute mesenteric ischaemia in this 
population. However, in the total population of the NUTRIREA-2 project, early 
full enteral nutrition was established to carry a higher risk of acute mesenteric 
ischaemia than no EN (Reignier et al., 2018). Among patients in study V, one 
presented with acute mesenteric ischaemia and very high I-FABP (>68000 
pg/mL) on admission to ICU. Unfortunately, the absolute values of I-FABP are 
not comparable between our study and the one by Piton et al, as different 
ELISA kits were used and their reference values differ greatly. Also, an impor-
tant consideration when interpreting results of study V is the fact that blood 
samples for biomarkers measurements were collected immediately after admis-
sion to ICU, facilitated by delayed informed consent. This may partly explain 
the very high I-FABP values seen in our study. Taking into account the rapid 
kinetics of I-FABP, significantly lower values are expected in trials with a more 
lengthy inclusion process, as in the NUTRIREA-2 substudy (Piton et al., 2019). 
There were no clear associations between the studied biomarkers and renal 
function. Reduced elimination of citrulline in renal failure could be expected 
from studies in non-critically ill patients. In critically ill patients, the presence 
of confounding factors may tend to decrease the values of the biomarker and 
counteract an increase due to renal failure, as hypothesised by Cynober (Cyno-
ber, 2013).   
All in all, somewhat conflicting signals of improvement of citrulline levels 
with EEN/ON and at the same time, possible enterocyte damage related to 
EEN/ON were seen. EEN and oral nutrition were considered together in study 
V, while calories provided with oral nutrition were not assessed. This short-
coming may affect the groupwise comparisons of patients with successful vs 
unsuccessful EEN/ON. Inclusion of short-staying, mostly postoperative patients 
with an incomplete dataset steered the citrulline values of the whole study popu-
lation higher on days 1 and 3, while I-FABP was not influenced. A relatively 
small patient population and substantial overlaps in the values of biomarkers 
between the compared groups calls for hypothesis-generation but does not 
invite to use these biomarkers in decision-making regarding nutrition of inten-




Results of the conducted studies consolidate the understanding of the impor-
tance of gastrointestinal problems and indicate areas where their diagnosis and 
management can be improved. 
1. Using a protocol to guide the administration of and troubleshooting related 
to enteral nutrition improves the delivery of nutrition via the enteral route in 
long-staying critically ill patients. This improved enteral intake is not 
related to more frequent gastrointestinal symptoms and intra-abdominal 
hypertension. With enhanced enteral nutrition, the use of parenteral nutri-
tion decreases and in a nutritionally challenging patient population with fre-
quent underfeeding, use of an enteral feeding protocol alone is not sufficient 
in avoiding large caloric deficits. 
2. Gastrointestinal failure, defined as the simultaneous presence of at least 3 
GI symptoms, occurs in one tenth of ICU patients and is associated with 
poor treatment outcomes. The importance of several concurrent GI symp-
toms is highlighted by the approach of defining GIF by the presence of 
multiple symptoms, where a higher number of simultaneous GI symptoms 
independently predicts long-term mortality similar to other organ dysfunc-
tions, characterised by the SOFA sub-scores. Primary and secondary GIF 
are both associated with high mortality, while GIF in a patient without a 
primary abdominopelvic pathology tends to occur in more severely ill 
patients, later in the course of critical illness, and possibly carry a worse 
prognosis. The monitoring of intra-abdominal pressure is warranted in pa-
tients that experience GIF as the prevalence of IAH is high in this patient 
group.  
3. Management options to treat sustained IAH and avoid its progression to 
ACS are limited, triggers to initiate treatment not clear and their effective-
ness poorly described. Our research underlines the pitfalls of sedation as a 
measure to reduce IAP. The effect of deepening of sedation on IAP is 
generally small, whereas many patients require vasopressor therapy to cor-
rect the hypotension ensuing from deep sedation. Nevertheless, a possibly 
clinically important decrease in IAP occurs in some patients and it cannot 
be excluded before a trial of sedation is undertaken. Therefore, deepening of 
sedation can be considered if IAH is considered as needing treatment, with 
careful evaluation of its effect and side effects. 
4. The newly developed GID score was created based on different GI symp-
toms, following the rationale of the AGI grading. The score demonstrated a 
good mortality prediction ability both individually and in addition to organ 
dysfunction sub-scores of the SOFA score. The biomarkers citrulline and I-
FABP did not contribute to the performance of the score.  
5. The biomarkers citrulline and I-FABP do not sufficiently discriminate 
between patients able to achieve their energy needs with EN from those who 
do not. Even though citrulline increases in patients receiving early enteral or 
69 
oral nutrition, possibly reflecting a recovery of enterocyte function, the 
direction and reproducibility of this association is not fully clear, and needs 
to be elucidated in further studies. A wide overlap in the values of citrulline 
and I-FABP among patients with early vs no early EN and successful vs 
unsuccessful EN currently does not favour their use in managing nutrition 
of intensive care patients.  
 
Future directions 
Acknowledging the importance of avoiding large cumulative energy deficits in 
long-staying ICU patients, a comprehensive approach to nutrition involving 
both EN and PN, as appropriate, should be consolidated into an improved nutri-
tion protocol. Further research exploring the effects of different nonsurgical 
management options to lower IAP are warranted. In the face of likely small 
effects of each individual measure, a bundle of measures to treat IAH could be 
developed and tested in a larger population. Even though citrulline and I-FABP 
did not prove themselves useful in our studies neither in guiding enteral nutri-
tion nor as components of the Gastrointestinal Dysfunction Score, the role of 
intestinal biomarkers in assessing GI dysfunction and non-occlusive mesenteric 
ischaemia will need to be elucidated. The Gastrointestinal Dysfunction Score 
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9. SUMMARY IN ESTONIAN 
Enteraalne toitmisravi, seedetrakti düsfunktsioon ja  
soole biomarkerid intensiivravipatsientidel 
Organpuudulikkuste diagnoosimine ja ravi on üks intensiivravi nurgakividest. 
Seedetrakti olulisust intensiivravipatsientidel on teadvustatud aastakümnete väl-
tel, kuid ometi on selle organsüsteemi düsfunktsioon ebapiisavalt defineeritud 
ning ei kuulu erinevalt teistest organpuudulikkustest intensiivravipatsiendi sei-
sundit kirjeldavatesse skooridesse. Seedetrakti düsfunktsiooni ja toitmisproblee-
mide diagnoosimine põhineb siiani peamiselt subjektiivsel kliinilisel läbivaatu-
sel. Võimalikud ravimeetodid seedetrakti probleemide lahendamiseks intensiiv-
ravipatsientidel ning nende tõenduspõhisus on vähesed.  
 
Uurimistöö eesmärgid  
Käesolev uurimistöö keskendus enteraalse toitmise läbiviimisele ja jälgimisele, 
seedetrakti düsfunktsiooni ja puudulikkuse diagnoosimisele ja mõju selgitami-
sele ning intra-abdominaalse hüpertensiooni ravivõimaluste uurimisele inten-
siivravipatsientidel.  
Täpsemad eesmärgid olid järgmised: 
1) selgitada enteraalse toitmise protokolli kasutusele võtmise mõju toiduenergia 
pakkumisele, seedetrakti sümptomite esinemissagedusele ja ravitulemustele 
pikaajalist intensiivravi vajavatel patsientidel (I uuring); 
2) kirjeldada mitme seedetrakti sümptomi samaaegse esinemise kaudu definee-
ritud seedetrakti puudulikkuse esinemissagedust, mõju ravitulemustele ja 
iseärasusi sõltuvalt tekkepõhjusest (II uuring); 
3) hinnata sedatsiooni süvendamise efektiivsust ja ohutust intra-abdominaalse 
hüpertensiooni ravis mehaaniliselt ventileeritud intensiivravipatsientidel (III 
uuring); 
4) luua seedetrakti düsfunktsiooni hindamiseks objektiivne skoor, kasutades 
selleks seedetrakti ja kõhukoopa poolseid sümptomeid, haigustunnuseid ning 
biomarkereid tsitrulliin ja I-FABP; hinnata skoori võimet ennustada ravi-
tulemusi (IV uuring); 
5) selgitada tsitrulliini ja I-FABP-i seoseid enteraalse toitmisraviga intensiiv-
ravipatsientidel (V uuring). 
 
Patsiendid ja metoodika 
I ja II uuring põhinevad prospektiivselt koostatud andmebaasil, kus sisalduvad 
kõigi alates 2004. aastast Tartu Ülikooli Kliinikumi 1. intensiivravi osakonda 
hospitaliseeritud patsientide olulisemad kliinilised andmed.  
I uuringus hinnati 2013. aastal kasutusele võetud enteraalse toitmise proto-
kolli mõju toitmisravi tulemustele. Selleks võrreldi retrospektiivselt 2011.–
2012. ja 2014.–2015. aastal osakonnas vähemalt ühe nädala jooksul ravil olnud 
patsientide ravitulemusi. Uuringus võrreldi kokku 480 täiskasvanud patsienti. 
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II uuringus analüüsiti retrospektiivselt 3959 täiskasvanud intensiivravi-
patsienti, keda raviti aastatel 2004–2015. Seedetrakti puudulikkuse defineeri-
miseks kasutati meie uurimisgrupi varasemalt kirjeldatud lähenemist – kolme 
seedetrakti sümptomi esinemine ühe päeva jooksul. Sümptomid olid: soole-
peristaltika puudumine, nasogastraalaspiraadi hulk >500 mL päevas, soolte laie-
nemine, oksendamine, seedetrakti verejooks, kõhulahtisus. Seedetrakti puudu-
likkus oli primaarne, kui arenes kõhukoopa- või vaagnapiirkonna patoloogiaga 
patsiendil, ning sekundaarne, kui oli seotud mõne muu haigusseisundiga. 
III uuring oli prospektiivne sekkumisuuring, mis hõlmas 37 täiskasvanud 
mehaaniliselt ventileeritud intensiivravipatsienti, kellel esines intra-abdomi-
naalne hüpertensioon. Kõhukoopasisese rõhu vähendamise eesmärgil süvendati 
patsientidel sedatsiooni propofooliga ning seejärel hinnati ühe tunni jooksul 
selle mõju intra-abdominaalsele rõhule, vererõhule ja vasoaktiivse ravi vaja-
dusele ning hingamisparameetritele.  
IV uuring oli mitmekeskuseline prospektiivne jälgimisuuring 9 riigi 11 
intensiivraviosakonnas, hõlmates 540 järjestikkust patsienti. Andmekogumine, 
mille rõhuasetuseks olid seedetrakti ja kõhukoopa sümptomid ning haigus-
tunnused, vältas ajal, mil patsient viibis intensiivraviosakonnas, ning maksi-
maalselt 7 päeva. Lisaks määrati osades uuringukeskustes (kokku 224 pat-
siendil) osakonda saabumisel ja seejärel igapäevaselt vereplasmast biomarkerite 
tsitrulliini ning I-FABP-i tase. V uuringus kirjeldati biomarkerite dünaamikat 
neil 224 patsiendil seoses varajase suukaudse või enteraalse toitmisravi ning 
selle edukusega. 
 
Peamised tulemused ja järeldused 
1. Toitmisprotokolli kasutuselevõtu järgsel perioodil manustati intensiivravi-
patsientidele esimese nädala jooksul enteraalse toitmise teel 40% võrra roh-
kem toiduenergiat kui enne toitmisprotokolli kasutuselevõttu. Sellega seoses 
ei suurenenud seedetrakti sümptomite ja intra-abdominaalse hüpertensiooni 
esinemissagedus. Siiski oli see kasv väiksem, kui samaaegne parenteraalse 
toitmise vähenemisest tingitud toiduenergia defitsiit. Kokkuvõttes vähenes 
pärast protokolli kasutuselevõttu nädala summaarne manustatud toiduenergia 
hulk. Parenteraalse toitmise vähesem kasutamine võis olla tingitud asjaolust, 
et patsiente toideti rohkem enteraalsel teel ning seetõttu pakuti parenteraalset 
toitmist väiksemale hulgale patsientidele. Välistada ei saa ka sekkumisest 
sõltumatut mõju, kuna protokolli kasutuselevõtu järgsel perioodil võidi 
eelistada parenteraalse toitmise hilisemat alustamist tulenevalt tol perioodil 
ilmnenud uutest teadmistest varajase parenteraalse toitmise kahjulikust mõ-
just ravitulemustele. Uuring osutas, et ainuüksi enteraalse toitmise protokolli 
rakendamisest ei piisa, et vältida suuri toiduenergia puudujääke. 
2. Kolme seedetrakti poolse sümptomi samaaegse esinemise abil defineeritud 
seedetrakti puudulikkus esineb 10%-l intensiivravipatsientidest ning on 
seotud halvemate ravitulemustega. Samaaegselt esinevate sümptomite oluli-
susele viitab asjaolu, et esimesel intensiivravipäeval esinev suurem seede-
trakti sümptomite arv on suremuse sõltumatu riskifaktor. Lisatuna SOFA 
85 
skoori alaskooridele parandab seedetrakti sümptomite arv mõnevõrra SOFA 
skoori võimet suremust ennustada. Nii primaarne, st kõhukoopa- ja vaagna-
piirkonna patoloogiaga seotud, kui sekundaarne ehk muu põhjusega seede-
trakti puudulikkus on seotud kõrge suremusega. Sekundaarse põhjusega 
seedetrakti puudulikkuse juhud leiavad sagedamini aset hilisemal intensiiv-
raviperioodil, patsientide seisund on raskem ning ravitulemused võivad olla 
kehvemad. Seedetrakti puudulikkusega patsientidel on intra-abdominaalse 
hüpertensiooni esinemissagedus kõrge ning kõhukoopasisese rõhu mõõtmine 
näidustatud. 
3. Intra-abdominaalse hüpertensiooni ravivõtted on piiratud, nende efektiivsus 
ebapiisavalt tõendatud ning näidustused ravi alustamiseks ebaselged. Käes-
olev uurimistöö osutab sedatsiooni süvendamise kui ühe intra-abdominaalse 
hüpertensiooni ravimeetodi vähesele toimele ja võimalikele kõrvaltoimetele. 
Sedatsiooni süvendamise tulemusena intra-abdominaalne rõhk küll vähesel 
määral langeb, kuid samal ajal leiab aset arteriaalse vererõhu oluline langus, 
mis põhjustab kõhukoopa perfusioonirõhu vähenemist ning ligi pooltel 
patsientidel on vaja alustada või tõhustada vasoaktiivset ravi. Siiski väheneb 
ligi veerandil patsientidest sedatsiooni süvendamise tulemusena intra-abdo-
minaalne rõhk oluliselt, mistõttu tuleks seda ravivõtet vajaduse korral kaa-
luda. Sellisel puhul on vaja võimalikke kõrvaltoimeid hoolikalt jälgida ja 
saadavat kasu analüüsida. 
4. Liikumaks edasi seedetrakti puudulikkuse kui dihhotoomse fenomeni kirjel-
damisest, töötasime välja seedetrakti sümptomite ja intra-abdominaalse hüper-
tensiooni raskusastmete kombinatsioonil põhineva kliinilise skoori – GIDS 
(GastroIntestinal Dysfunction Score). Biomarkerid tsitrulliin ja I-FABP 
skoori toimimist ei parandanud. Loodud skoori võime ennustada suremust 
oli hea nii iseseisvalt kui lisatuna SOFA skoorile.  
5. Tsitrulliini ja I-FABP-i tase vereplasmas ega ka markerite dünaamika ei või-
maldanud ennustada toitmisravi edukust enteraalset toitmisravi saavatel 
intensiivravipatsientidel. Ehkki tsitrulliini tase on kõrgem varajast toitmis-
ravi saavatel patsientidel, viidates seosele enterotsüütide funktsiooni taastu-
misega, ei ole selle seose olemus selge ning vajab edasist uurimist. Tsitrul-
liini ja I-FABP-i väärtuste suur kattuvus võrdlusrühmade vahel ei võimalda 
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